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ABSTRACT 
The dissertation aims to discuss the disulphide and thiol chemistry for use in drug delivery. 
In particular it focuses on the use of the modified native ovalbumin polymer as a vehicle for 
the thiol containing captopril. The binding capabilities of thiols expand the area in which 
peptides and proteins can be used as potential therapeutic drug carriers. It is important that 
drug delivery systems enhance drug storage stability and in vivo particle stability while 
delivering the drug efficiently. As part of the developing novel drug delivery systems, thiol-
based chemical reactions are distinctive role players in stabilizing disulphide bioconjugated 
nanostructures for use as efficient drug carrier vehicles in vivo. A review of the current 
approaches for designing, optimizing and functionalizing nanostructures and conjugates by 
thiol chemistry modifications was explored. Captopril (Cp) is an Angiotensin-Converting 
Enzyme (ACE) inhibitor, which acts as an anti-hypertensive, structurally contains a free 
reactive thiol that binds variably via the thiol/disulphide reaction. A single dose of captopril 
can regulate hypertension for up to eight hours and the duration of the antihypertensive 
action of a single dose of 35-75 mg would be taken at 8 hour intervals for 24 hours. Hence 
the necessities in developing a sustained controlled release ovalbumin carrier system to 
maintain relatively constant blood pressure levels for 24 hours. The research focused on the 
construction, characterization and optimization of the thiol conjugated complex for sustained 
oral drug delivery. The thiol/disulphide-functionalized captopril-ovalbumin conjugate complex 
was assessed in terms of the structural characteristics and the thiol-disulphide covalent 
substitution reaction. For analysis of the conjugation complex, the Fourier Transmission IR-
spectroscopy (FTIR), H+ NMR and Differential Scanning Calorimetry (DSC) was performed 
and used to confirm conjugation. Preliminary studies focused on a comparative study of 
sodium alginate, polyvinyl alcohol and hydroxypropylmethylcellulose hydrogel formulations 
for the release testing and drug entrapment of the ovalbumin-captopril conjugate complex. 
Utilizing this data, a series of process variables were used to achieve an optimized 
formulation through a Box- Behnken statistical design. Furthermore the drug release profiles 
of the optimised formulation were then analyzed in vitro and in vivo. The captopril released 
from the formulation was high with a cumulative release of 82%. In vivo analysis was the 
final testing to verify the validity of the ovalbumin-captopril conjugate complex encapsulated 
in sodium alginate and utilized a pig model. Ultra Performance Liquid Chromatography 
(UPLC) blood analysis revealed increased blood levels of captopril (Cmax Cp=33.2ng/mL) in 
relation to conventional dosage forms validating prolonged (24 hour) site-specific release 
and increased bioavailability. In conclusion, our validated method was successfully applied 
to the pharmacokinetic studies of captopril in the blood plasma samples. 
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 CHAPTER 1 
Novel Application of Ovalbumin as an Effective Drug Delivery Vehicle 
   
1.1. Introduction 
It is important that drug delivery systems enhance drug storage stability and in vivo particle 
stability (Leach et al.,2005), while delivering the drug efficiently. The use of natural polymers 
has become of interest in recent years, with a shift from the usual use of synthetic polymers 
and surfactant polymers. In research studies, questions on the toxicity of the synthetic 
polymers and surfactants have been investigated but have not yet been fully resolved 
(Leach et al.,2005). Some studies have investigated possible substitutes to the synthetic and 
surfactant polymers (Mantalva et al.,2008). One of which being the use of natural polymers, 
where in some instances such as in protein nanotechnology, or so called biopolymers, are 
used in drug delivery systems (Randolph et al.,1997; Judge et al.,1996; Sakai et al.,1999; 
Sobotka et al.,1961). Some of these biopolymers are used as supplements and agents for 
carrying vitamins and oils. The choice of polymer is dependent on biopolymer strength, 
rigidity and the ability to form a matrix. 
In a study performed by Aimi et al., (2009), casein was investigated for its ability to deliver 
different active agents for uses such as transdermal, digestive and disease treatment agents 
Andrews et al.,2000. From the above findings, biopolymers can be used as efficient drug 
delivery systems for various drugs, at low cost to the manufacturer. The challenge has been 
in designing a natural polymer for use for drug delivery applications, following a simple, 
reproducible biopolymer or like that is biodegradable, increases bioavailability and has little 
or no toxicity and side effects on patients. Factors such as drug loading, particle size and 
shape, water-air interface and adhesion relative to drug molecules must be superior to 
commercially available drug delivery vehicles. The encapsulation of the drug delivery vehicle 
must enhance particle storage while enhancing increased drug stability and target site 
delivery of the drug. 
In the oral administration of drugs, it is important that drug delivery vehicle becomes entero-
soluble and absorbable by the intestinal mucosa. Properties such as mechanical strength, 
resistance to enzyme degradation and resistance to fluid moisture must be efficient. The 
type of protein used in the synthesis of the biopolymers determines the characteristics of the 
polymer vehicle. 
Proteins found in egg white for example, can be formed into drug delivery vehicles. Whey 
protein has been researched for its foaming, emulsifying and stability characteristics (Banta, 
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2007). It has been reported that the difficulty experienced with the structural properties of 
whey protein, has been with whey protein converting into a poor strength gel when exposed 
to slightly high pH (Challa et al.,2005). This is attributed to the most abundant protein found 
in whey protein, ovalbumin. Ovalbumin, a 45kDa monolithic protein, was also tested in high 
temperatures, where numerous results showed that ovalbumin is water-insoluble, and forms 
aggregates or lamellar sheets under increased heat of 80°C (Creighton, 1993). It was 
reported that the aggregates formed micelles when they were exposed to salts such as 
sodium, potassium, or the like (Huntington et al.,1997). Physicochemical and 
physicomechanical studies later revealed that ovalbumin had increased surface pressure 
and hydrophobicity characteristics due to its foaming abilities (Gupta et al.,2005). This has 
since led to the investigation of ovalbumin providing stable modes of drug delivery to certain 
sites in the animal model. The possibility of ovalbumin contributing to the stability and 
crosslinking with other polymers in drug delivery, to stabilise, increase tertiary structure 
strength and provide a versatile drug delivery vehicle polymer exists. 
 
1.2. Rationale and Motivation 
The design of the polymeric drug carrier system should: 
 Ensure thiol to thiol conjugation between the polymer and the bioactive. 
 Be site specific in the release of the bioactive without chemically modifying the 
bioactive. 
 Release from the vehicle easily by unbinding to form a free thiol.  
  Demonstrate the versatility of the thiol binding sites and their potential use as drug 
carrier systems.  
 Demonstrate the reversible covalent binding properties in vivo of the disulphide-thiol 
chemistry reaction.  
Polymer therapeutics has proven to be effective in conjugating biocompatible polymers to 
therapeutic proteins or drugs for improved drug, protein or gene delivery. Biocompatible 
polymers are extensively used and have important role in modern pharmaceutical sciences; 
nonetheless there is a demand for the ever-increasing application of more efficient polymer 
chemistry to innovate new and diverse pharmaceutical polymers (Roper et al.,2004).  
Thiols are formed through various ways, some of which include the exogenous exposure to 
enzymatic cleavage and chemically reducing or oxidizing disulphide interactions. The most 
common way of producing thiols is the use of enzymes which act by cleaving the disulphide 
bonds between two cysteine residues (Li et al.,2009). 
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The limitations of using the above mentioned chemicals have been the instability. The 
approaches for the degradation of the disulphide bonds ensure that the thiols are available 
for interactions in shorter periods of time. Thiols can reversibly be cleaved in the presence of 
reducing agents such as dithiotheitol (DTT), tris(2-carboxy-ethyl) phosphine (TCEP), 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (EDC), 2-iminothiolane, thioglycolic acid and 
hexandithiol (HDT) (Chan et al.,2009; Lowe et al.,2009) to mention a few. 
These modifications exhibit the potential binding sites of thiol groups found in all natural and 
some synthetic protein polymers. The advantages of using thiols as binding sites for 
biopharmaceutical bioactives is that (1) they have demonstrated increased structural stability 
in the process of polymer synthesis, (2) have shown multifaceted reactions that thiols can 
form, (3) demonstrated the versatility of the thiol binding sites and their potential use as drug 
carrier systems. The novelty of thiol reactions has been their reversible covalent binding 
properties in vivo. 
The rationale was to synthesize of a multifunctional drug carrier system was to enable the 
bioconjugation of any thiol containing bioactive while remaining stable in vitro and in vivo. 
The novel ovalbumin polymer was to be used as the carrier because of its natural internally 
buried disulphide bonds that would provide excellent potential sites for bioconguation. 
The success of an effective drug delivery system may be evaluated completely by stability 
studies. The sole purpose of stability testing is to obtain a stable product which maintains its 
efficacy to the maximum shelflife at specific storage conditions and maintain peak drug 
release profiles. The advantages of a stable formulation are: 
• Prolonged residence time at the site of action  
• Localization of dosage form at a specific site 
• Increased drug concentration gradient across the intestine, increasing contact of the 
drug particles with the mucosa 
• Direct contact with the intestinal cells, which preceeds particle absorption (Rashid et 
al., 1990). 
 
1.3. Novelty of the Study 
The novelty of the study was the use of a native polymer, namely ovalbumin, that contained 
thiol binding sites for bioconjugation. The ovalbumin polymer when modified provided 
reactive thiol sites for the conjugation of the thiol-based bioactives such as captopril, which 
make ovalbumin a novel drug carrier system. The functional novelty of thiol reactions has 
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been their reversible covalent binding properties in vivo. The benefits of using ovalbumin 
thiol-based chemistry in the delivery of drugs include; 
 Thiols demonstrate increased structural stability in polymer synthesis. 
 Improved patient compliance thus aiding in the reduction of frequency in the oral 
administration captopril thus aiding in the control of hypertension. 
 The possibility of using native polymers such as ovalbumin in the fabrication of 
pharmaceutical dosage forms for sustained delivery of drugs. 
 The generation of scientific data for publication in high-impact peer reviewed journals 
and presentation at conferences.  
 
1.4. Aim of the Study 
The aim of the study was to design an efficient, target specific drug delivery vehicle that 
would enhance the delivery of thiol-based bioactives. This was achieved by designing 
modified ovalbumin vehicles for oral administratiion and intra-mucosal absorption. The 
chemically modified ovalbumin vehicles were manipulated to achieve the desired dosage 
form by meeting the following objectives; 
 
1. Characterization and the assessment of the native ovalbumin properties such as the 
thermal response, and physical stability in response to pH, salt and temperature 
variations.  
2. Analyse the chemical characteristics of the functional groups and assess the 
potential sites for possible interactions with crosslinking polymers and the properties 
of the bonds formed. 
3. Elucidate the conjugation efficiency, morphological characteristics, zeta-potential and 
size and thermal properties of the complex conjugate. 
4. Compare different hydrogel polymers suitable for the encapsulation of the ovalbumin 
drug carrier system. Furthermore determine the Fourier transform infrared 
spectroscopy and thermal properties of the hydrogel ovalbumin particles. 
5. Determine parameters affecting the dissolution rates of the chemically modulated 
modified ovalbumin particles and the bioavailability of captopril. 
6. Fabrication and optimization of the composite polymeric vehicle carrier system in the 
capsule dosage form, comprising of ovalbumin, sodium alginate and calcium 
chloride. 
7. Performance of in vivo animal studies in the Large White pig model to determine 
release and bioavailibilty of captopril. 
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1.5. Overview of the dissertation 
Chapter one introduced the prospect of a new material for use as a drug delivery carrier. It 
exemplifies the use of natural polymers for the purposes of drug delivery and the challenges 
associated with the use of natural polymers. A chemical altering technique was proposed 
and rationalized to create a highly stable vehicle matrix with increased surface area to 
efficiently control the release of the drug from the system. The design of the polymer would 
be manipulated to enhance drug release and achieve the desired drug release profiles. The 
aims, objectives and technology proposed for designing the drug carrier vehicle were 
provided in this chapter.  
Chapter two was a review that highlights recent interests and applications of disulphide and 
thiol chemistry in creating contemporary macromolecular designs for drug delivery. Due to 
the chemical nature of disulphides and thiols a wide range of chemical species react with 
these functional groups to yield a variety of polymers extending their applications in 
chemical, biological, physical, material engineering and material sciences. The review aimed 
to illustrate the versatility and demonstrate the potential of thiol-based chemistries. The focus 
is on exploring bio-cleavable disulphides and linking by “clicking” thiols via thiol/other 
functional group exchange reactions. 
Chapter three demonstrated the thiol conjugation of the natural polymer to a bioactive. The 
research was aimed to analyse the ovalbumin polymer after disulphide modification. The 
chapter was aimed to assess the thiol/disulphide functionalization of the captopril-ovalbumin 
interaction, the structural characterization and mechanical properties of the conjugate 
complex and to report on the thiol-disulphide covalent substitution reaction. The ATR-FTIR, 
differential scanning calorimetry, rheological analyses were employed to assess the 
chemical and physicochemical properties of the captopril-ovalbumin conjugate complex as a 
drug carrier system. The results demonstrated the stability and functionality of the native 
polymer in carrying and stabilising the bioactive, without chemically compromising the 
bioactive and its pharmacodynamics. 
 
Chapter four provided a comparison of the three hydrogels used to encapsulate the 
captopril-ovalbumin conjugate complex. The aim of the chapter is to examine the 
pharmacokinetics of three main hydrogel polymers known for their controlled release 
properties namely, sodium alginate, 2-hydroxy propyl methyl cellulose and poly vinyl alcohol. 
These above mentioned hydrogels exhibited bioadhesive properties that could potentially 
increase the release of the bioactive across the intestinal mucosa. The results verified the 
best encapsulating hydrogel for the captopril-ovalbumin conjugate complex. It resulted in the 
high percentage drug release, drug encapsulation and prolonged release of the captopril. 
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Chapter five was an assessment of the parameters affecting the pharmacokinetics of the 
ovalbumin drug carrier system. These parameters gave insight on the preformulatory factors 
affecting the release of captopril, by exploring the responses of the lower and upper limits of 
the components that synthesized the captopril-ovalbumin drug delivery system. The 
parameters also provided insight into the interactions between the polymers and the salt 
concentrations. The limits of the parameters were, but were not limited to, the polymer 
concentrations and salt concentration. The responses demonstrated the resultant effect on 
drug release. The results showed that the higher the salt concentrations, the less drug was 
released. The variation in the polymer concentrations showed that no stastical significant 
difference was found between the upper and lower limits of the polymer concentrations.  
 
Chapter six described the optimisation procedure of the drug delivery system. The Box-
Behnken design for optimisation of the drug delivery system was assessed and reported on. 
The interactions assessed the responses of each component of the drug delivery system on 
the effects of accumulated drug release, particle size, zeta-potential and mean dissolution 
time. The results were reported on and the suitable combination of polymer concentration 
and salt were chosen for the optimized ovalbumin drug carrier system. 
 
Chapter seven describes the in vivo assessment undertaken on the ovalbumin drug carrier 
system. The pig model was used to assess the pharmacokinetics and pharmacodynamics of 
the system. Blood samples were analysed using the UPLC to determine the concentrations 
of the captopril released in vivo. A validation method was also determined and applied for 
the quanitification of the model drug, captopril.  
 
Chapter eight summarises the conclusions of the ovalbumin drug delivery system and 
recommendations for further studies.  
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CHAPTER 2 
Disulphide/Thiol Chemistry: Macromolecular Design and Synthesis of Polyfunctional 
Material for Drug Delivery 
 
2.1. Introduction  
Polymer therapeutics is a term largely used to describe polymeric drugs, polymer conjugates 
in the form of polymer-drug or -protein conjugates, polymeric micelles or gels to which drugs 
are covalently bound (Duncan, 2003). Polymer therapeutics has proven to be effective in 
conjugating biocompatible polymers to therapeutic proteins or drugs for improved drug, 
protein or gene delivery. Biocompatible polymers are extensively used and have important 
role in modern pharmaceutical sciences; nonetheless there is a demand for the ever-
increasing application of more efficient polymer chemistry to innovate new and diverse 
pharmaceutical polymers (Roper et al.,2004). One interesting and fast advancing tool used 
in polymer science is the use of thiol chemistry in polymer synthesis.  
Thiols are formed through various ways, some of which include the exogenous exposure to 
enzymatic cleavage and chemically reducing or oxidizing disulphide interactions. The most 
common way of producing thiols is the use of enzymes which act by cleaving the disulphide 
bonds between two cysteine residues (Li et al., 2009). Enzymatic cleavage of the covalent 
disulphide bonds results in the complete separation of the two amino acid strands which 
results in a longer duration of separation. The problem with using enzymes has been the 
reformation of disulphide bonds with other proteins especially in redox plasma environments, 
such as at cellular and plasma levels. Enzymatic cleavage causes a transformational change 
in the protein which results in rebinding on the protein (Judy, 2011; Bumcrot et al., 2006). 
The other ways of cleaving the disulphide bonds is by oxidising or reducing the bonds using, 
for example, performic acid or 2-mercaptoethanol and iodoacetic acid. The limitations of 
using the above mentioned chemicals have been the instability and the duration required for 
the bonds to separate. Both approaches for the degradation of the disulphide bonds ensure 
that the thiols are available for interactions in shorter periods of time.  
In some instances for example in, lactoglobulins which have three thiol groups, and in 
ovalbumin four thiol groups are buried in the interior of the protein (Onda, 1997).The thiol 
groups (SH), are formed spontaneously when exposed to air. As mentioned above, thiols are 
produced either by partial heating of the protein, by acid induced denaturing of the 
disulphide bonds or by salt induced denaturation. These external stressors modify the 
ovalbumin protein by chemically separating the disulphide bonds; in some instances by 
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causing partial unfolding of the primary structure, exposure of the hydrophobic bonds, 
oxidation or reduction of covalent bonds and introduction of the hydrogen bonds. The above 
mentioned modifications ultimately result in either the disintegration of the tertiary structure 
or varying the degrees of denaturation of the protein. The half-life of the reaction RS-SR + 
2e → 2RS- has a standard reduction potential of 0.25V and therefore oxidation could be 
carried out in mild conditions (Roth et al., 2011). Unfortunately the thiol chemistry of 
macromolecular proteins such as ovalbumin have not yet been extensively reported and 
researched, hence this review seeks to explore the other thiol related chemistry of polymers. 
Polymers that contain thiol groups have generally been referred to as thiomers.  Thiols can 
reversibly be cleaved in the presence of reducing agents such as dithiotheitol (DTT), tris(2-
carboxy-ethyl) phosphine  (TCEP), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 2-
iminothiolane, thioglycolic acid and hexandithiol (HDT) (Chan et al.,2009; Lowe et al.,2009) 
to mention a few. In some instances thiols have been expressed in proteins using DTT for 
example, creating stability or improving drug binding efficiency to the delivery systems as will 
be demonstrated in the review. Thiomers are mostly used due to their ability to act as very 
good mucoadhesive polymers. The covalent bonds in the form of disulphide bonds enable 
the thiomers to bind mucus surfaces of the mucosa of the gastrointestinal wall. The thiomers 
act by binding onto proteins, glycoproteins, drugs and carbohydrates through the disulphide 
covalent bonds. Binding capabilities of thiols expand the area in which peptides and proteins 
can be used as potential therapeutic drug carriers. 
Proteins and peptides have been used as the primary bases for protein drug delivery 
especially in the advancement of gene therapy, genetic engineering, molecular biology and 
also to improve drug binding efficiencies. The benefits of using macromolecular peptides and 
proteins in drug delivery are encompassed in the fact that they are readily available, are 
endogenously biodegradable and can be produced in commercial quantities. Proteins are 
also important as they are employed in the regulation and integration of life systems at 
nucleic and organ level. Enzymes, hormones and antibodies are for example highly specific 
in their binding sites on both receptors and antigens. The specificity of the binding sites in 
these proteins, enable peptides and proteins to specifically bind to a limited number of sites 
without compromising the efficiency and effectiveness of the bond formed in terms of both 
excellence and enhancement of stability. To date, different peptides have been used in drug 
delivery. Proteins and peptides continue to display the importance as future drug delivery 
carriers because of the ever increasing advancement in molecular biology, identification and 
discovery of hormones, their usefulness and broad application as biopharmaceuticals and 
lastly their regulatory roles in human pathophysiology. The present review also aims to 
explain the potential binding sites of thiol groups found in all natural and synthetic proteins. 
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Overall this review provides a detailed account on the advantages of using thiols as binding 
sites for biopharmaceutical bioactives, illustrate their functionality in polymer synthesis, show 
the multifaceted reactions that thiols can form and lastly demonstrate the versatility of these 
binding sites and their uses in drug delivery systems. 
Some of the reactions will be briefly discussed because they are not the focal points in this 
review. The main reactions that will be discussed are those that are relevant in thiol-based 
chemistry used primarily in thiol polymer synthesis, modification and functionalization. Table 
1 shows some examples of thiol chemistries and illustrate some of the thiol chemistry 
reaction classifications. The specific examples used in this review aim to illustrate the 
versatility, functionality and speciality of thiols being used in drug delivery and material 
science.  
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Table 1. Examples of Thiol Reactions used in Polymer Synthesis [Reproduced with 
permission from Roth et al., 2011, © WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim].  
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2.2. Thiol-based click chemistry  
As part of the developing a realm of novel drug delivery systems, researchers have recently 
recognized several thiol-based chemical reactions as ‘click’ chemistry reactions. The 
strength of many thiol chemistries are based on the ability of the highly inherent reactive 
groups to react readily with a wide array of functional groups under a variety of experimental 
conditions, that do not necessarily affect the bond formed. The main challenge that was 
postulated for the thiol-based chemistries in polymer and material science, was the 
modification of the conditions or ‘masking’ of the thiol reaction to produce thiol bond 
formation at the specific regions required on the polymer or material. The term ‘click’ 
chemistry, first coined by Kolb et al.,(2001) referred to as a series of simple reactions that 
were facile, rapid, and quantitative and site specific (Hein et al.,2008). According to Kolb et 
al., in order for the reactions to be considered as ‘click' they have to meet six basic 
requirements as follows: i) the use of cheap, readily available material; (ii) maintain ease of 
execution; (iii) be able to form a high quantitative yield in drug delivery that meets the 
requirements to be classified as click chemistry reactions, even though there has been 
scepticism about the consideration of thiol-based chemical single target product; (iv) be 
environmentally friendly; (v) require non-chouromatographic purification at the last stage; 
and lastly (vi) have regiospecific targeting. 
Kolb et al. also noted that the orthogonality of thiols, facile and high reactivity were generally 
compromised, hence Lowe and Harvison (2010) pointed out that the thiol click chemistry’s 
strength was also its weakness in chemistry. This has been evident in the reduced number 
of publications that link thiol-click chemistry with polymer or material science. In the following 
sections thiol-chemistry will be discussed in the context of polymer synthesis, functionality 
and modification in drug delivery systems. The thiol-chemistry reactions used throughout the 
review are those that were conducted in the absence of possible competitive functional 
groups and side-reactions and under appropriate conditions with characteristic click thiol-
based-chemistry environments.  
There are three main types of thiols; namely the thiolate, thiol ion and the thiyl radicals that 
exist. Hoyle and Bowman (2010) distinguished four basic structures of thiols reported in 
literature, namely alkyl thiols, thiophenols, thiol propionates, and thiol glycolates. These 
above mentioned thiol structures influence the chemistry of thiols, which determines whether 
they are catalysed before reactions or are in a radical state for reactions to occur. The 
chemical natures of the thiol functional groups provide interesting reactivity in that they 
readily react with very useful and available organic substrates. Thiols react with alkynes, 
electron poor enes (Michael Addition), isocynates (carbonyl addition), epoxies (SN2 ring 
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opening) and halogans (SN2 nucleophilic substitution) and especially the electron rich enes 
(radicals). Figure 1 depicts the general thiol structures with multifunctional thiols. 
 
 
 
Fig. 2.1. General thiol structures including multifunctional thiols [Reproduced with permission 
from Lowe et al., 2010 © The Royal Society of Chemistry].   
 
Two general forms of disulphides are known namely, the asymmetric and the symmetric 
disulphides (Scheme 1). The asymmetric disulphides are disulphides obtained by using 
thiol/disulphide exchanges while symmetric disulphides are obtained by oxidising the 
disulphide bond using oxidising reagents such as iodine, iron chloride and oxygen (Roth et 
al., 2011). The readily reactive thiol groups permits for the creation, functionalization and 
modification of a range of polymers with a diverse array of physical, chemical and 
mechanical properties for use in drug delivery that meet extensive biological and bioactive 
delivery requirements. The use of multiple thiol click reactions support the original concept of 
click chemistry reactions of synthesising a wide array of chemical and more elaborate 
materials within a short period of time under chemically and friendly environmental 
conditions.   
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Scheme 1. Structure and synthesis of asymmetric and symmetric disulphides [Reproduced 
with permission from Roth et al., 2011 © WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim]. 
 
The most well-documented thiol-based click chemical reactions in drug delivery are the 
multiple carbon-carbon bonds. Two specific multiple carbon-carbon click reaction groups, the 
thiol-ene and thiol-yne reactions dominate in polymer sciences especially in drug delivery. 
Other thiol-based click reactions such as the thiol-epoxy, thiol-isocyanate, thiol-halogen 
nucleophilic substitution and thiol nucleophile-mediated Michael addition click chemistries 
exist. Nucleophilic thiol reactions rely on the nucleophilicity of the thiol reactive group, and 
tend to proceed at rates that are determined by the substrate and its proclivity for the 
nucleophilic attraction by either the thiols or the thiolate anions (Killpos et al., 2008; Lowe et 
al., 2010; Hoyle et al., 2004; Gress et al., 2007). In some instances the rates of the above 
mentioned reactions become determined by the choice of catalysts, which accelerate the 
reactions to achieve high conversions. Most of these nucleophilic reactions are initiated by 
strong nucleophilic bases. The above mentioned thiol click chemistry will be discussed 
briefly hereunder. 
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2.2.1. Thiol-epoxy click reactions 
Hoyle et al., (2004) described the epoxy-thiol click reaction, used in many important 
biosynthetic and biomedical applications, as a straightforward ring opening nucleophilic 
reaction by the thiolate anion. The consecutive step involves the protonation of the alcolate 
anion by the quaternary ammonium, originally formed by the base catalyst and the thiol to 
generate a thiol anion. The reaction is catalysed by a variety of strong bases through 
deprotonation of the thiol.  
An example of the functionality of the epoxy-thiol reaction is the formation of Sepabeads to 
stabilise the enzymes on the surfaces of proteins using the epoxy-thiol supports. The 
science behind the formation of the Sepabeds demonstrated by Mateo et al., (2007), 
illustrate the stabilisation of proteins that support the retardation of the enzyme, to promote 
adsorption of the enzyme and create a rigid protein that allows the retardation of the enzyme 
whilst promoting enzyme binding or attachment. The key purpose of this work was to create 
a heterofunctional enzyme, penicillin G acylase (PGA) that would ultimately assist enzyme 
attachment and re-use of the enzyme. By modifying the enzyme to generate multiple 
covalent attachment points using dithiothoureitol, ensured the disulphide exchange between 
the two thiol surfaces. Sodium sulphide was also introduced onto the enzyme as an 
additional thiol additive at pH 7 to create the rigid thiolated enzyme surface structure. The 
outcome was an improved specific immobilisation of the enzyme by the exchange in thiols 
between the enzyme and the protein disulphide bonds of the modified protein (Figure 2.2). It 
was reported that the stabilization factor for the PGA complex increased by 12-15 fold 
compared to previous counterparts.  
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Fig.2.2. The covalent attachment reaction between epoxy and the thiolated protein 
[Reproduced with permission from Mateo et al., 2003 © American Chemical Society]. 
 
The thiol-epoxy reactions continue to be of interest in drug synthesis and drug delivery 
material synthesis as they continue to develop rapidly in applications of drug synthesis, 
bioactives and biological processes of numerous synthetic materials. The ring-opening 
reactions especially those involving thiols and epoxy have been reported to be important in 
industry because of their adhesive and highly functional coatings used in synthons and in 
optical fields.   
 
2.2.2. Thiol-isocynate nucleophilic addition click reactions  
This sulphur analog of the polyurethanes, polythiourethanes, have been ineptly explored as 
potential drug delivery materials in past years. The polythiourethanes have mostly been 
used in industry and recently in polymers for improved high macromolecular weight polymer 
architect synthesis (Matsushima et al., 2010) in the last two decades. The nucleophilic 
addition of the thiols to isocyanate groups has been reported to yield high products within 
seconds of reacting the monomers, dimers and trimers. Very few articles have been 
published that show the versatility of the polythiourethanes; but their use as efficient optical 
materials has been exemplified. Their use in optical materials on a commercial and industrial 
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scale expanded primarily due to the high refractive index properties that the 
polythiourethanes exhibit.  
Shin et al., (2010), explored the mechanical and viscoelastic properties of the 
polythiourethanes using multifunctional thiols and diisocynates. The reaction was either 
photochemically or thermally initiated to achieve controlled sequence thiol-ene 
photopolymerization. Triethylamine (TEA) and 2,2-dimethoxy-2-phenyl acetophenone 
(DMPA) were used to initiate the formation of the thiol-isocyanate in the presence of the 
base catalyst tributylamine 3 tetraphenylborate (TBA-3-HBPh4). The nucleophilic addition of 
thiols to isocyanate groups in the presence of a strong base catalyst is depicted in Scheme 
2a. The thiol-isocyanate coupling kinetics of the hybrid were analysed and found to yield 
quantitatively rapid and efficient conversions of >90%, within minutes and seconds of 
exposure to one another. The glass transition temperature of the hybrid increased from -5 to 
35°C, as a function of the thiourethane content because of the higher covalent hydrogen 
bond which ultimately resulted in enhanced mechanical properties. The hybrid network 
structure formed highly uniform and dense network structures. These results are indicative of 
the relationship between chemical composition and physical mechanical properties, 
specifically those of calorimetry, hardness, thermal and tensile properties of the hybrid 
network.   
Shin et al., (2009) do, however, emphasise the rate of reaction between the thiolate anion 
and isocyanate with use of the correct catalyst as being slow. They highlight the fact that 
strong bases, with higher conjugate acid pKa values, are essential for the formation of the 
thiolate anion and affect the outcome of the thiol-isocyanate coupling reaction rate. The 
investigators illustrated an example of a sequential thiol-isocyanate reaction, and also 
characterized the thermal and mechanical properties of the polythiourethane elastomers. In 
this specific example 1,6-hexanedithiol (HDT) was reacted with butenediol diacrylate, in 
presence of catalyst, Me2PPh, which resulted in the formation of a flexible, soft 
polythiourethane oligomeric  polymer. Scheme 2b depicts the synthetic pathway of the novel 
polythiourethane elastormers employing the segmented thiol-isocynate coupling. The 
thermal and ‘dynamic’ mechanical property was evaluated based mostly on the chemical 
composition following polymerization. It was noted that the glass transition and cross linking 
density decreased with the increase in the thiol content. The tensile properties were 
dependant on the micro-separation and mixing of the phases. 
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Scheme 2. (a) Tertiary Amine Catalyzed Thiol-Isocyanate Nucleophilic Coupling Reaction 
Mechanism [Reproduced with permission from Shin et al., 2010 © American Chemical 
Society]. (b) Synthesis of novel polythiourethane elastormers employing the segmented 
thiol-isocynate coupling. Adapted from Materials Chemical [Reproduced with permission 
from Shin et al., 2009 © American Chemical Society]. 
  
2.2.3. Thiol-halogen nucleophilic substitution click reactions 
Thiols are generally soft nucleophiles, which makes their substitution rapid and efficient by 
readily displacing groups such as halogens, and form thiol-halogen nucleophilic reactions. 
Rosen et al.,2010, illustrated that the nucleophilicity of the thiol in 2-mercaptoethanol was 
very high compared to other thiol-dialcohol species added on halogenated and 
functionalised polymers and other halogen containing polymers. This illustrated that the thiol-
halogen ion affects the orthogonality of the nucleophile thiol-halogen reaction, because the 
thiol anion displaced the halogen even in the presence of high concentrations of alcohol 
groups and aliphatic amines.   
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An astute example of the nucleophilic halogen substitution reaction that was demonstrated 
by Samaroo et al., (2007) which involved four para fluoro groups on 5,10,15,20-tetrakis-
(2,3,4,5,6-pentafluorophenyl)-porphyrin (TPPF20) that were used to bind biopolymers such 
as DNA and small proteins that could be taken up by cells and nuclei in cancer cells. In this 
specific study TPPF20 was used to create motifs to assist in inducing breast cell apoptosis 
and necrosis. The results show that the 20-30nm size particles that were formed were found 
to be able to cross the blood brain barrier. The reaction yield was high and demonstrated the 
successful binding of the thiols onto the para fluoro. The entire reaction is illustrated in 
Figure 2.3. 
 
Fig. 2.3. Nucleophilic halogen substitution reaction using Para fluoro for conjugation to small 
biopeptides   [Reproduced with permission from Samaroo et al., 2007 © American Chemical 
Society].  
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Becer et al., (2009) synthesized glycoproteins constituting homopolymers styrene and 
pentafluoro (PF). The thiol-glycoside was created by using a catalyst, to create 
pentafluorostryene (PFS), and the resulting self-assembled nanospheres had an average 
diameter of 70-720nm when using the nanoprecipitating method. For the addition of thiols on 
the backbone of PFS, a thiol-glycoside (2,3,4,6-tetra-O-acetyl-1-thio-D glucopyranose), was 
used to exchange the thiol with the para-fluoro to the polymeric backbone of the PFS 
moieties (Figure 2.4). The reaction was reportedly monitored by 1H, 13C 19F NMR 
spectroscopy and size exclusion chouromatography. The synthesis of glycopolymers via the 
nucleophilic substitution of the para fluoro click displacement reaction proves that the free 
thiol fluorine could be used as a method of preparation in dendrimer and bioorganic 
functionalization of the nanoparticles for the application in a wide range of tailor made 
macromolecules suited for drug delivery, nanotechnology and catalysis. 
 
 
 
Fig. 2.4. Preparation of glycopolymers from pentafluorostyrene (PFS) reaction with SH-
GlcAc4 (2,3,4,6-tetra-O-acetyl-1-thio-β-d-glucopyranose) [Reproduced with permission from 
Becer et al., 2009 © American Chemical Society].  
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2.2.4. Thiol-ene/Thiol-yne Michael-type addition click chemistry 
There has been immense interest in thiol-ene and thiol-yne click chemistry especially in their 
application and functionalization in polymer and material science. The progress in this area 
has been due to unique polymer functionalization and regiospecifity advantages when 
compared to previous traditional coupling and functionalization strategies. The newly 
invented methods for the formation of materials in drug delivery are attributed to the robust 
nature of the thiol-ene and thiol-yne chemistry for the synthesis of well defined materials, 
with few structural limitations and synthetic requirements. In the following section the 
formation of thiol-enes, network and dendrimer formations and modification by accessorising 
three-dimensional objects are discussed. 
The thiol-ene/thiol-yne reaction has been known for over a 100 years and is simply defined 
as the hydrothiolation of the carbon=carbon bond. Previously thiol-enes/thiol-yne were used 
to prepare near-perfect networks and films to be used in polymer or drug delivery because of 
the attractive and versatile chemical features that they exhibit. Kade et al., (2010) noted that 
data had shown that the structural regularity of the thiol-ene and thiol-yne were more regular 
than those networks formed by diacrylates. A number of factors attribute to the thiol-
ene/thiol-yne reaction being facile, versatile and attractive as a future drug delivery tool. 
Lowe (2010) highlighted three main features associated with thiol-ene/thiol-yne versatility. 
The hydrothiolation reactions were ensued in a variety of conditions including radical 
pathway, catalytic processes by nucleaphiles, acids and bases and supramolecular catalysis 
using, for example, cyclodextrins. Thiol-enes/thiol-yne generally serves as suitable 
substrates for activated and inactivated functional group species and as ‘multiple-substitution 
olefinic bonds’ (Mather et al., 2006; Yu et al., 2009). Lastly, any free radical thiol can be 
employed depending on the sulfur-hydrogen bond strength and cleavage mechanism, 
whether homolytic or heterolytic lysis. As part of click chemistry features the reactions occur 
rapidly in mild conditions and in the presence of oxygen and the resulting product, the 
‘thioether’, improves regiospecificity. The thiol-ene and thiol-yne are the radical thiols that 
are generally used by photopolymerization to form complex networks used in polymer 
science.  
Heredia et al., (2010) synthesised a heterotelechelic biotin-maleimide cleavable disulphide 
bond by RAFT polymerization for reversible surface modification with proteins. The 
incorporation of cleavable disulphide bonds in this example illustrated that the ‘cleavable 
handle’ provided for capture and release of the protein and substrate. Chain transfer agents 
containing disulfide bond mediated the polymerization of NIPAAm to α-biotin disulfide, ω-
trithiocarbonate-pNIPAAm.  Trithiocarbonate was coupled radically to a maleimide initiator 
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which resulted in a heterotelechelic α-biotin disulfide, ω-maleimidepNIPAAm. The method of 
synthesis used the retro- Diels Alder reaction. The polymer was then conjugated using the 
disulphide bond to either bovine serum albumin or mutant V131C T4 lysozyme (T4L) and 
anchored onto streptavidin- or neutravidin-functionalized surfaces. The reversibility of the 
polymer conjugate was demonstrated by surface-anchored protein maintained activity 
towards antibodies. 
Connal et al., (2009) stabilized and functionalized polymer multilayers and capsules using 
the thiol-ene click chemistry. They reported the synthesis of the layer-by-layer assembly of 
hydrogen bonded multilayers and deposition of methacrylic acid which contained thiol 
groups (PMAthiol). Poly(vinylpyrrolidine) (PVP) was combined with PMAthiol to form coated 
PVP/PMAthiol nanoparticles which were subjected to UV-light. Figure 5 depicts the 
transmission and scanning electron microscope images of the PVP/PMAthiol-ene 
nanoparticles. 
 
 
 
Fig. 2.5. Microscopy images of layer-by-layer assembly of hydrogen bonded multilayers by 
alternately depositing poly(methacrylic acid) containing either thiol groups (PMATHIOL) or ene 
functionality (PMAENE), with poly(vinylpyrrolidone) (PVP), at pH 4, 
(PVP/PMATHIOL/PVP/PMAENE)2/PVP on silica particles and resulting thiol−ene PMA 
(PMAT−E) capsules upon selective removalbuminl of the core and exposure of the particles to 
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pH 7. (a) Phase contrast image of UV-irradiated coated particles at pH 4 and the 
corresponding fluorescence microscopy image (inset). (b) Fluorescence microscopy image 
of UV-irradiated PMAT−E capsules at pH 7. (c) Transmission electron and (d) scanning 
electron microscopy images of PMAT−E capsules at pH 7. PMA was labelled with AF488. 
[Reproduced with permission from Connal et al., 2009 © American Chemical Society]. 
 
2.3. Thiol-Based Defined Architectures Containing Disulphide Conjugates 
2.3.1. Hyperbranched/Mulitiarmed star polymers 
Hyper branched polymers are generally used to encapsulate and isolate functional groups 
from external media that may easily conjugate to free moieties from. The main idea was to 
isolate the functional groups from reacting with the surrounding organic functional groups 
and for biomedical applications (Helms et al., 2005). Various methods have been used in the 
synthesis of these hyper branched polymers, where use of disulphide linkers which target 
either the arm or the cores of the polymer structure were employed. Initially the arm 
approach was easier to achieve since the target was generally on the extremities of the 
polymer. The assembly of the hyper branch required the pre-synthesis of the primary linear 
chains which were consequently coupled to the functional core or polymerised and linked 
using a cross-linker to achieve highly functional hyper branched polymers. Different methods 
have been used to prepare, for example, multi armed star polymers such as hetero-Diels 
Alder reactions (Barner et al.,2006), alkyne-azide reactions (Gao et al.,2009) thiol-ene 
reactions (Liu et al.,2008), and thiol-pyridal disulphide reactions (Iha et al.,2009).  
Roth et al.,(2011) described the synthesis of multi armed star polymers is achieved using 
three different strategies namely, the “core first” approach, the “arm first” approach and the 
“coupling to” approach. Iha et al., (2009) explained the approaches as follows: i) the core 
first approach was when the arms of a star polymer were developed from multifunctional 
initiators; ii) the arm first approach was when the coupling of pre-synthesised macro-initiators 
or macro-monomers with a cross linker to form a star occurred; while iii) the coupling 
approach entailed the process when pre-synthesised polymer chains were added onto 
multifunctional cores. The core and arm first approached were generally employed to add 
functionality to a polymer by using functional monomers, from pre-synthesized block 
copolymers. In comparison to the coupling approach the synthesis of the star polymer is 
limited by the efficiency and selectivity of the reaction used in the conjugation step.  
Kamade et al., (2011) synthesised poly(n-butyl acrylate)-based star polymer consisting of 
the monomers n-Butyl acrylate (BA) and ethylene glycol diacrylate (EGDA). The polyEDGA-
(polyBA) was synthesised using the atom transfer radical polymerization method by 
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employing the core first approach. The above mentioned complex was further polymerized 
using the arm first approach to produce a disulphide cross-link star polymer. In this specific 
example the use of arm and core first approaches are conjugated to form a redox responsive 
star polymer. The addition of thiols by the cross-linker bis(2-methacryloyloxyethyl) produced 
the disulphide functionality, which was cleaved via reducing reactions, resulting in individual 
stars with thiol ends. The thiol ends were reversible by repetitive oxidation and reduction. 
The diameter of the star polymers was 20nm and the mechanical properties were conclusive 
of the oxidation and reduction conditions. The authors concluded that such stimuli 
responsive polymers had a great potential application in self-healing materials. Figure 6 
illustrates the redox behaviour of the thiol/disulphide star polymer. 
 
 
Fig. 2.6. a) Synthesis of the functionalised poly(n-butyl acrylate) star polymer; and b) 
Reduction and oxidation of the disulphide/thiol functionalised star polymer [Reproduced with 
permission from Kamada et al., 2010 © American Chemical Society]. 
 
2.3.2. Micelles  
Wong et al., (2008) used an anticancer drug, doxorubicin for grafting onto RAFT-synthesized 
poly(pyridyldisulfide ethylmethacrylate) PPDS polymer. The method employed was the thiol-
ene and thiol-yne click addition reactions which provides efficient drug delivery vehicles. The 
Dox-PEG complexes were covalently conjugated to thiol groups on the PPDSM in the 
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presence of disulphide reducing agent, dithiothreitol (Figure 2.7). The average size of the 
micelles was 192nm. The micelle nanoparticles were viable in inhibiting human cervical 
carcinoma cells. Roth et al., (2011) noted that micellar instability had become a limitation for 
in vivo applications as micelles only function and maintain stability above their critical 
micellar concentration (CMC). To bypass this limitation, micelles were crosslinked with 
linkers such as adding cleavable bonds, using pH sensitive chemical functional groups that 
are easily reduced or modified to assist in the reversibility of the bonds formed. 
 
 
Fig. 2.7. Synthesis of the thiol functionalised poly(pyridyldisulfide ethylmethacrylate); 
Doxorubicin-conjugated complex with PEGylated disulphide crosslinked particles prepared 
by RAFT polymerization [Reproduced with permission from Wong et al., 2008 © American 
Chemical Society]. 
 
Micelles are normally cross-linked using biodegradable linkers, such as disulphides or pH-
sensitive groups, because cleavable linkers such as disulphides have proven to provide 
reversible stabilisation. Dufresne et al., (2005) synthesised surface modified colloids for 
selective interactions with biological surfaces as drug delivery systems. Poly(ethyleneglycol)-
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block-poly-(2-(N,N-dimethylamino)ethyl methacrylate) was synthesised with a thiol end. The 
micelles were designed to specifically recognise streptavidin. Mucoadhesion was also 
assessed through the formation of disulphide groups with the surface mucins. The efficiency 
of the system was conveyed by the ability of the intermicellar disulphide bonds generated 
under oxidative stress to promote the formation of stimuli responsive micellar networks. 
 
2.3.3. Nanogels 
Nanogels are potential drug delivery systems especially in their applications in drug and 
gene delivery. Nanogels are networks with interior and exterior properties that allow water or 
physiological fluid to distend the network structure which has similar characteristics to 
hydrogels and nanoparticles (Oh et al., 2008). Tan et al., (2011) explain that nanogel sizes 
offer additional properties advantageous to nanogel networks such as increased surface 
area for bioconjugation, entrapment of biomolecules such as drug, proteins, carbohydrates, 
and DNA, and the immediate response to external stimuli. Nanogels have attracted attention 
in material science for use in cosmetics, biotechnology and medicine. Morimoto et al.,(2008) 
prepared dual responsive nanogels which were able to alter their responses to redox and 
temperature conditions. Poly (N-isopropylacrylamide) (PNIPAM)-grafted polysaccharides 
were prepared with end thiols. The PNIPAM chains were grafted with pullulan which was 
treated with sulfanylthiocarbonylsulfanyl (STS), to functionalize the conjunction between 
PNIPAM and STS. The PNIPAM-grafted pullulan was then aminolysed to thiols. The 
nanogels were found to swell slightly on cooling and the nanogel sizes were approximately 
102nm, in water and upon reducing the disulphide bonds, the average size of the particles 
were approximately 55nm at a temperature of 50°C. Tan et al., (2011) synthesised thiolated 
hydroxypropyl cellulose (HPC-SH) as a means of preparing dual-sensitive self assembled 
fabricated nanogels. The HPC-SH maintained the thermosensitivity of the HPC and the thiol 
groups were oxidised to form disulphide bonds. The oxidation of the thiol groups was to help 
the HPC-SH to stabilize the association structure. The HPC-SH was easily disassociated by 
reducing the disulphide bond using dithiothoureitol (DTT) and the temperature affected the 
hydrodynamic radius of the HPC-SH architect. Scheme 3 depicts the basic concept of thiol 
thermo/redox responsive mechanism (Roy et al., 2010). 
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Scheme 3. Basic concept of thiol thermo/redox responsive mechanism [Reproduced with 
permission from Roy et al., 2010 © Elsevier B.V. Ltd]. 
 
2.3.4. Hydrogels 
Synthesis of biodegradable gel can be achieved by two methods: i) the copolymerisations of 
monomers in the presence of disulphide-containing crosslinkers; and (ii) the oxidation of 
multi-thiol containing polymers such as di/trifunctional telechelic thiol polymers. Wu and co-
workers [69] demonstrated the synthesis of “living” controlled in situ gelling system which 
uses the thiol-disulphide exchange reaction. The branched “living” hydrogel was synthesised 
by the Michael addition polymerization binding 1-(2-aminoethyl)piperazine (AEPZ) with N,N′-
bis(acryloyl)cystamine (BAC) to yield a core-shell branched polymer, poly(BAC2-AEPZ1)-
PEG (BAP). The formation of the “living” in situ hydrogel caused the activation, interruption, 
termination and reactivation by manipulating the pH of the system. The resultant hydrogel as 
described by Wu et al., (2010) were biocompatible, biodegradable, easily fabricated with 
certain desired shapes, size and properties (Figure 2.8). The thiol-disulphide exchange 
reaction was in this instance used to countercheck whether the rearrangement brings 
forward the intended meaning-otherwise correct as it may be appropriate so as to ultimately 
manage to control the formation of the gel, which acted as an on and off function.  
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Fig. 2.8. a) The synthesis of branched Poly(BAC2-AEPZ1)-PEG (BAP); and b) the thiol-
disulfide exchange reaction which causes the formation of cross-linked Poly(BAC2-AEPZ1) 
cores [Reproduced with permission from Wu et al., 2010 © American Chemical Society]  
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2.3.5. Thiomers 
The uniqueness of using thiol-based polymers is their ability to form mucoadhesive polymers 
capable of forming covalent bonds with cysteine rich residues from other proteins. The ease 
of forming covalent bonds with various surfaces such as the mucosa achieves various 
effects. Some of which enhance contact to the absorptive mucosa that favour drug 
absorption and bypass enzymatic degradation. Bernkop et al., (2005) also noted that the 
prolonged retention time of short biological half-life of certain biopharmaceutics was 
improved and resulted in better patient compliance for drug delivery systems.  
The most common thiolated polymer researched for most drug delivery systems was 
thiolated chitosan (Bernkop et l, 2005; Bravo-Osuna et al., 2006, Bravo-Osuna et al., 2007; 
Bravo-Osuna et al., 2007). Some other researched polymers include the hydrophilic 
polymers poly(acrylates) (Greimel et al.,2006; Palmberger et al., 2007; Greindl et al.,2006; 
Iqbal et al.,2006)or deacetylated gellan gum (Krauland et al., 2003; Narkar et al., 2010; Cao 
et al., 2009)The above mentioned polymers contain thiol groups on their side chains. The 
unique characteristic of the disulphide bond especially as a tool in drug delivery is its 
reversibility and its relative stability in plasma.  
 
2.4. Bioconjugation for drug delivery  
Bioconjugation strategies have been employed in many drug delivery systems via the use of 
linkers Kamada et al., (2010). Proteins moieties and molecules have been used to form 
protein-protein, protein-molecules and protein-drugs interactions. The attachments of cellular 
and subcellular moieties, drug delivery enhancing molecules and the functional groups to the 
drugs have become essential and important in modern day drug delivery. The success of the 
linker between the bioactive and the drug delivery system determines the degree of success 
of the system and its effect. The problems highlighted by Saito et al., (2001) associated with 
the above mentioned linkers have been in the increase of the drug weight especially in 
macromolecular carriers, pharmacokinetics of the drug delivery system and metabolism of 
the macromolecule. As previously explained, Dharap et al., (2005) had used the LHOURH 
peptide to create a polymer drug delivery carrier which targeted the ovalbuminrian, breast 
and prostate cancer cells. The drug delivery carrier was designed to firstly induce apoptosis, 
secondly to target moieties and enhance penetration, and lastly to carry the anti-cancer drug 
to the specific tumor site. The LHOURH results showed that the hormone enhanced the 
above mentioned and targeted responses. Vlies et al., (2010) synthesised pyridyl 
functionalised nanoparticles for small molecules, peptides and proteins. The nanoparticles 
were designed to carry thiol reactive groups, to which other thiol containing antigens and 
biomolecules would bind in non-thiol competitive environments. The pyridyl functionalised 
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nanoparticles were 25nm in size and permitted efficient release of the antigen intracellularly. 
Hydroxyl and carboxylic polymers were used in the emulsion with propylene sulphide. 4-arm 
thioester was added and polymerised and functinalised by adding iodoacetamide (Figure 
2.9). 
 
 
                  Fig.2.9. Conjugation of the carboxylated nanoparticles and pyridyl disulphide yielding 
Ovalbumin protein biologically-functionalized: (a) Hydroxyl-Pluronic and carboxylate-Pluronic 
are used to make an emulsion with propylene sulfide. (b) To the emulsion is added four-arm 
thiol initiator, and polymerization is started by addition of base. After polymerization, particles 
are exposed to air to cross-link, and the remaining thiolates are end-capped with 
iodoacetamide. (c) The carboxylate-nanoparticles are reacted with pyridyl disulfide 
cysteamine to yield thiol-reactive functionalizable nanoparticles. (d) Conjugation of thiol-
containing biotin, AcSDKDSLKCGOH peptide, and ovalbumin protein gives biological-
functional nanoparticles. [Reproduced with permission from Vlies et al., 2010 [85] © 
American Chemical Society]. 
 
2.4.1. Disulphide bond linkages  
Covalent linkages have been commonly used for the reversibility and stability of these bonds 
in drug, molecular and protein interactions (Madea et al., 2009). The recent focus has been 
in utilizing covalent disulphide bonds in creating stably expressed drug delivery systems. 
The unique characteristics of the disulphide bond are its reversibility and relative stability in 
the plasma. Saito et al., noted that the high redox potential difference between the oxidizing 
extracellular space and the reducing intracellular space has made the disulphide bond 
feasible as a successful delivery tool. The application of these thiol-based conjugations have 
achieved targeted bioactive delivery, enhanced cellular cytosolic delivery, improved 
pharmacokinetics and also an improved stability of the formed bond. Cayot et al., (2002) 
used electrochemical modifications of proteins in order to cleave the disulphide bonds. It was 
reported that at pH 10 and 11 the disulphide bonds were reduced.   
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2.4.2. Creating thiols via chemical and molecular approaches 
The conjugation of two molecules via disulphide bonds need two free sufhydryl groups that 
are either exogenously introduced or found readily existing between two cysteine amino 
groups. Many approaches have been adopted in drug delivery to create these thiol groups, 
some of which include incorporating thiol group moieties onto the polymer or chemically 
modulating the polymer to express its own thiol groups as mentioned above. The former is 
achieved by introducing cysteine derivatives onto the polymer and the latter is achieved by 
the chemical modification of the polymer, such as using oxidation or reduction to expose the 
buried thiol groups, considering modification of any polymer generally result in a slight 
decline in its efficacy. The other way that thiol groups could be introduced onto a polymer is 
by using hetero-bifunctional linkers. These linkers are found exposed on the surfaces of 
lysine residues or the N-terminal residues. Some examples of these linkers are 2-imithiolane 
and N-succinimidyl S-acetylthioacetate (SATA) (Frandse et al., 2012). Conjugating 
approaches such as site specific conjugation of cysteines introduced into recombinant 
expressed protein are achieved by directing the amino acid to a specific site for amino acid 
substitution. This approach has been beneficial especially with the use of newly genetically 
modified proteins for enhanced drug delivery (Olas et al., 2010). Weber et al., (2000) 
prepared surface modified nanoparticles by introducing exogenous thiols onto the surface of 
human serum albumin (HSA). The thiol groups were introduced by reducing the aldehyde 
residues with dithiothreitol or 2-imithiolane for attachment onto the surface HSA 
nanoparticles, which resulted in well defined characterised thiol surface. The thiols were 
highly stable with a half-life of 28.2 days.  
 
2.4.3. Disulphide drug delivery mechanisms 
There are three main approaches in disulphide linkages that are generally employed by drug 
delivery systems, the first being the employment of macromolecule for endocytosis across 
the plasma membrane (i.e. in the cells), secondly cytosolic delivery of macromolecules and 
lastly cleavage of the disulphide in the systemic circulation, which are briefed as under.  
 
2.4.3.1. Macromolecular drug delivery uptake via endocytosis  
The uptake of macromolecular drugs by endocytosis has proven to be beneficial and 
effective as a mode of drug delivery. One example includes the use of antibody targeted 
chemotherapy drugs that use disulphide bonds to release anti-carcinogenic drugs upon 
cellular internalisation (Singh et al., 2008). Endocrine glands such as the pancreas, liver and 
stomach are generally known to have the ability to cleave disulphide bonds or oxidise the 
bonds utilising hormone cleavage. In cells, the cellular compartments have been targeted 
such as the Golgi apparatus, endosomes, lysosomes and the plasma membrane. These 
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sub-cellular organelles show potential thiol interaction sites because of their free thiol group 
moieties which enable easy disulphide formation creating improved binding and stability 
between the drug-drug for the drug delivery vehicle to be efficient.  
 
2.4.3.2. Attachment by targeting moiety through thiols 
Moieties provide good sites for attachment. The free accessible thiol groups are increased in 
number and show improved number of stably expressed thiol groups that can bind strongly 
onto a linker, conjugate complex or a hydrogel. The creation of moieties occurs by the 
addition of the thiol moiety which can be controlled by synthesizing stably expressed 
conjugates that are stable in the systemic circulation (Chi et al., 2003). 
The importance of using interchangeable disulphide bonds is that they create stability in the 
drug delivery system as a whole; they also create relatively stable covalent bonds to 
modulate the stability of the formulation in an aqueous environment (Pitaressi et al., 2008). 
Disulphide bonds are also important in stabilising and assembling small proteins such as 
genes, viruses and bacteria. It has however been noted in a study done by Pitarresi et al., 
that the increase in disulphide interactions between drug delivery system and the mucosa of 
the intestine was decreased due to strong bonds that were not easily cleaved thus resulting 
in reduced drug release profiles.  
 
2.4.3.3. Disulphide cleavage in the circulatory system 
Blood plasma generally has an oxidising environment and the reduction of disulphide bonds 
occurs frequently in the systemic circulation because of the low concentrations of cysteines 
present in the body. The disulphide bonds are eventually cleaved resulting in increased 
release of the drug or polymer in blood circulation. The bioconjugate or linker is also 
designed to decompose the amino component ensuring biodegradability of the polymer or 
carrier to enhance drug release. 
 
2.5. Mucoadhesive nanoparticulate system 
Biodhesion onto the intestinal mucous membrane was popularised by Longer et al. in 1985. 
Longer et al., (1985) were the first to prove that intestinal mucosal bioadhesion improves 
drug absorption by increasing the drug residence time. This led to a delayed gastrointestinal 
transit which improved drug absorption and controlled the drug released from the drug 
delivery device. The most common dosage form used for mucoadhesion was in a tablet or a 
capsule form. This was achieved by coating the tablet with Carbopol and hydroxypropyl-
methylcellulose. Bern-Schurp and co-workers (Bravo-Osuna et al., 2007; Cevher et al., 
2008; Cevher et al., 2008; Chopra et al., 2008; Davidovich-Pinhas et al., 2009) adopted 
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chitosan as a mucoadhesive polymer and have since proven that chitosan provides good 
mucoadhesive properties. Chitosan has also been used in an array of drug delivery systems 
for example transdermal patches (Grabovac et al., 2008) because of its permeation 
enhancer properties (Imam et al., 2003). It has even been used in transfection (Loretz et al., 
2007) as well as a cysteine conjugate (Schimtz et al., 2008; Werle et al., 2007; Werle et al., 
2007; Reinwarth et al., 2012;Werle et al., 2006). Furthermore Chitosan has been utilised for 
its application in oral non-viral gene delivery (Martein et al., 2007) and nasal delivery of 
bioactives (Krauland et al., 2006). Notably, bioadhesive polymers have become important in 
delivering poorly absorbable drugs since their inception in the 1990s.  
Peptide drugs are gastroenterologically poorly absorbed owing to their high molecular weight 
and hydrophilicity, not to mention their quick biodegradability by gastric enzymes (Hamman 
et al., 2005). The concept of delivering peptide drugs orally would have been ideal if they 
could bypass enzyme degradation in the stomach and remain intact until when they become 
absorbed or released. This concept has been applied to other delivery systems such as 
pulmonary (Luppi et al., 2009), vaginal (Bernkop-Schnurch et al., 2003), nasal (Sharma et 
al., 2010) and ocular (Vijay et al., 2008) drug administration systems via the mucous 
membranes. 
 
2.5.1. Improvement of thiomers for enhanced mucoadhesion 
To improve mucoadhesion in animal models two basic concepts have been adopted, the first 
one being targeting of the mucus gel layers in the pulmonary, ocular and the vaginal 
systems, while the second one is the in situ cross-linking process: 
 
2.5.1.1. Formation of disulphide bonds with the mucus gel layer 
Disulphide bonds form between two thiol groups between the thiomer and the mucus gel. 
Mucins in particular the mucus glycoproteins, exhibit cysteine rich subdomains that provide 
desirable potential sites for thiomer attachment. The rate of disulphide bond formation 
between two surfaces depends on the concentration of the thiolate anions between the two 
or three potential binding sites. The concentration of the thiolate anions has been reported to 
be mainly affected by the pKa of the thiol group, the pH of the thiomer and the pH of the 
surrounding medium (Peppas et al., 2009). The pKa of the thiol group mostly affects the 
polymer backbone and the chemical structure of the conjugate by causing instability in the 
backbone. The pH of the thiomer such as in ionic thiomers, which are commonly used, 
display high buffer capacity (Albrecht et al., 2007). It has also been noted that the reactivity 
of the thiomers can be controlled by adjusting the pH of the polymer to a certain level. The 
higher the pH of the polymer the more thiol reactivity and vice versa. The pH of the 
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surrounding medium determines the reactivity of the thiols on the surface of the polymer 
Bernkop-Schnurch et al., 2006). The mucus layer in this instance has a pH of 7, allowing the 
thiols to react and penetrate the mucus layer efficiently. 
 
2.5.1.2. In situ cross-linking process  
The other mechanism used to improve the mucoadhesive properties of thiomers has been 
the cross-linking properties. The mechanism works on the basis of thiol bonds forming 
additional disulphide bonds within the polymer itself after cross-linking with the gel. This has 
led to an improved anchorage of the polymer with the gel layer which results in the 
stabilization of the drug delivery carrier (Ho et al., 2010; Sreenivas et al., 2008)). The 
mechanism improves the adhesive properties by improving penetration of the polymer 
device and increasing the stability process. It has been demonstrated that thiols oxidised at 
physiological pH-values result in the formation of inter- and intramolecular disulphide bonds 
(Jauhari et al., 2006; Wang et al., 2009). These findings were confirmed by rheology, 
diffusion, gel permeation and mucoadhesion studies. It was also found that the rheological 
properties of thiolated polymers helped to improve the elasticity of the gel because of the 
immobilized thiol groups which resulted in higher elastic modulus (i.e. G’). In the case of 
anionic thiomers, the tensile properties were improved by 2 to 20-fold while viscosity 
correlated to in situ cross-linking (increased by 10-fold). The intestinal residence time was 
also improved by 3-fold.  
 
2.5.1.3. Dosage forms of thiomers 
Shaji et al., (2008) reported that thiolated nanoparticles easily disintegrate because of the 
oxidation of the sulphate ion, but when calcium ions and sulfonate ions were bound to them 
they tended to inhibit disintegration. This led to stabilisation of the cross-linking process; 
however this caused a reduction in the mucoadhesive properties of the nanoparticles. The 
immobilisation of the thiol groups in turn resulted in the improvement of the mucoadhesive 
properties by forming disulphide bonds within the thiomer and the mucin surface thus 
increasing the stability of the drug delivery system. The double binding of thiols resulted in 
the particles not disintegrating easily under physiological conditions. The size of the particles 
also contributed to the prolonged residence time. 
Thiomer matrices are useful for intraoral, peroral, ocular and vaginal administration. The 
cross-linking properties of thiomers guarantee the cohesiveness and stability of the carrier 
matrix (Loretz et al., 2007). The dry matrix tablet adheres and interpenetrates more easily 
depending on the swelling behaviour of the delivery system. The hydration state of the tablet 
will determine the cohesiveness of the drug delivery system, hence targeting moist or well 
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hydrated areas permits for better adhesion and penetration behaviour of the system (Malik et 
al., 2007). In addition, thiomers provide advantageous controlled drug delivery systems 
which have been previously proven to be effective and sufficient, in this example by 
homogenising the thiomer with a drug and compressing the system to a tablet form yielded 
guaranteed zero order release delivery system for several hours. The formation of thiomer 
tablets are predominately controlled by hydration states of the environment in which they are 
to be administered and the diffusion process between the administration layer and the 
thiomer. The vagina and nasal cavity provides an attractive alternative for drug delivery 
systems compared to the oral delivery of drugs. The vagina and nasal cavity permit for 
peptides, protein carriers and drugs to attach covalently on the mucus surfaces resulting in 
efficient residence time on the mucosa (Morishita et al., 2006).  
Challenges surrounding liquid formulations as novel drug delivery systems have always 
been rather obvious because of residence time that the drug delivery system has in contact 
with the adhesion surface. A comparison between tablet and liquid formulations that involved 
mucoadhesion microdisc engineered for ophthalmic drug delivery, revealed that liquid 
formulations were previously inefficient as drug delivery systems due to their shortened 
residence time (Thompson et al., 2011). Thus, most of the ophthalmic formulations were 
improved by adding mucoadhesive polymers that could enable them attach easily and 
quickly on the surface.  
 
2.5.1.4. Current sulfur conjugates 
An interesting recent expansion of the use of thiols has been the in conjugating thiols to 
metal atoms. Clusters of the thiol-metal conjugates such as gold conjugated to p-
mercaptobenzoic acid (Au102(p-MBA) and Au25(SCH2CH2Ph)18),  have been successfully 
synthesised in neutral and anionic charge states (Gupta et al., 2009; Heaven et al., 2008). In 
a recent study performed by Kacprzak et al., (2010) and Seib et al., (2006) the thiolate ion 
was conjugated to copper, silver and gold. These metal-thiolate complexes containing 
flexible bond motifs demonstrate structural monocylic rings, catenanes and helix structures 
which often compete in energy when analysed using structural, vibrational and electronic 
studies. Of the three metal-thiolates, copper was found to be the strongest metal to sulphur 
bond (Cu-S), followed by gold (Au-S) and lastly by silver (Ag-S). The most interesting feature 
of vibrational analysis was the covalbuminlency between the Au-S bond, whereas the Cu-S 
bond was the most polar of the three. This vibrational result shows the ability of the covalent 
thiolate to bond better with a polar motif than a covalent metal, in this case Au. Unfortunately 
due to poor solubility the applications of metal-sulfur complexes are relatively few. 
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2.6. Concluding Remarks 
The review illustrated the potential versatility of synthetic and natural approaches for 
designing, optimizing and functionalizing nanostructures and conjugates by thiol chermistry 
modifications. The examples used in the review illustrate the power and adaptability of thiols 
for site specific functionalization, the construction of complex macromolecules and the 
generation of both biodegradable disulphides and non-biodegradable bonds. In addition, the 
ability of thiols to react with various functional groups found in various polymer science 
materials and peptide related structures were demonstrated. In spite of the fact that research 
efforts in thiol chemistry is still in the initial stages, it is likely that its true potential has yet to 
be discovered. It is however anticipated that thiol chemistry will be used as an effective tool 
in drug delivery and as a drug carrier systems. 
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CHAPTER 3 
Disulphide/Thiol Covalent Chemistry: A Method for Preparing Selectively 
Functionalised Captopril-Ovalbumin Drug Delivery Conjugates 
 
3.1. Introduction 
Polymer therapeutics is a term largely used to describe polymeric drugs, polymer conjugates 
in the form of polymer-drug or -protein conjugates, polymeric micelles or gels to which drugs 
are covalently bound (Hein et al., 2008). Polymer therapeutics has proven to be effective in 
conjugating biocompatible polymers to therapeutic proteins or drugs for improved drug, 
protein or gene delivery. Biocompatible polymers have played very important roles in 
modern pharmaceutical sciences; nonetheless there is demand for the ever-increasing more 
efficient polymer chemistry to innovate new and diverse pharmaceutical polymers (Cramer et 
al., 2004; Li et al., 2009; Roth et al., 2011; Bumcrot et al., 2006). One interesting and fast 
advancing tool used in polymer science is the use of thiol chemistry for polymer synthesis, 
functionalization and conjugation.  
Disulphide groups are known to degrade into sulfhydryl groups in the presence various 
reducing agents. The sulfhydryl groups otherwise known as thiol functional groups (SH) are 
formed spontaneously when exposed to air by autoxidation or reduction (Judy, 2011; 
Kosters et al., 2003). When reduced the resulting thiols can rebond to form disulphide 
bonds. Thiols can also be produced by either partial heating of the protein (Alting et al., 
2002), by acid induced denaturing of the disulphide bonds or by salt induced denaturation 
(Alting et al., 2000; Alting et al., 2003; Moad et al., 2011). The majority of thiol chemistries 
used for polymer science material and in drug delivery were performed on the ends of 
Reversible Addition Fragmentation Chain Transfer (RAFT) polymers, derived by reacting 
thiol containing compounds to form the self assembled multi-arm polymers (Boyer et al., 
2009; Back et al., 1979).  
 
A different approach that can be adopted in polymer science is to polymerise protected thiols 
and expose them in the presence of thiol-reducing reagents. Naturally occurring proteins 
such as ovalbumin generally have disulphide groups buried in the interior of the protein 
which makes these proteins attractive alternatives to the use of synthetic polymers. 
Ovalbumin is one of the major egg-white proteins (60-65%) with a molecular weight of 
42.7kDa (Huntington et al., 1997). The protein is a non-inhibitory member of the serine 
inhibitor (serpin) super-family and has secondary structure elements of α-helix and β-sheet 
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(Smith et al., 1965). Ovalbumin has one ‘solvent-accessible’ disulfide bridge and four free 
sulfhydryl groups buried in the interior of the protein.  
 
External stressors can modify the ovalbumin protein by chemically separating the disulphide 
bonds, in some instances by causing partial unfolding of the primary structure, exposure of 
the hydrophobic bonds, oxidation or reduction of covalent bonds and introduction of the 
hydrogen bonds. These modifications would ultimately result in the either the disintegration 
of the tertiary structure or varying the degrees of denaturation of the protein. The half-life of 
the disulphide/thiol reaction RS-SR + 2e-       2RS- has a standard reduction potential of 
0.25V and therefore oxidation could be carried out under mild conditions (Huntington et al., 
2001) .  
 
 
                                                                                                                                                                                                                                                                                                                                   
Fig. 3.1. A schematic illustrating the conjugation of one molecule of ovalbumin cysteine 
conjugating to captopril yielding biologically-functionalized ovalbumin vehicle carriers.  
 
These modifications exhibit the potential binding sites of thiol groups found in all natural and 
some synthetic protein polymers. The advantages of using thiols as binding sites for 
biopharmaceutical bioactives is that (1) they have demonstrated increased structural stability 
in the process of polymer synthesis, (2) have shown multifaceted reactions that thiols can 
form, (3) demonstrated the versatility of the thiol binding sites and their potential use as drug 
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carrier systems. The novelty of thiol reactions has been their reversible covalent binding 
properties in vivo. One such covalent reaction includes the thiol containing bioactive 
pharmaceutical captopril. Captopril (Cp; 1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline) 
(Cp) is an Angiotensin-Converting Enzyme (ACE) inhibitor, which acts as an anti-
hypertensive and binds to proteins via the thiol/disulphide interactions (Cotarelo et al., 2006). 
The properties of the reaction include the reversibility of the sulphide bond in comparison to 
other drug-protein interaction in the presence of reducing agents such as dithiothreitol.  
 
The thiol chemistry of macromolecular proteins such as ovalbumin has not yet been 
extensively reported on, hence the aim of the research is to analyse the ovalbumin polymer 
after disulphide modification. The chapter was aimed to assess the thiol/disulphide 
functionalization of the captopril-ovalbumin interaction (Figure 3.1), the structural 
characterization and mechanical properties of the conjugate complex and to report on the 
thiol-disulphide covalent substitution reaction.  
 
3.2. Material and Methods 
3.2.1. Materials  
Quial hen eggs wee purchased from Pick ‘n Pay Hypermarket. Purified lyophilised ovalbumin 
(OVA), Dithiothreitol (DTT), 2-Mercaptoethanol (2-ME) and 5’5 Dithio-bis nitrobenzoic acid 
(DTNB) and captopril were purchased from Sigma (Sigma Aldrich, Missouri, USA). Ethanol, 
Tris EDTA salt, NaCl2, Potassium phosphate monobasic and Disodium hydrogen phosphate 
were purchased from Merck (Merck KGaA, Darmstadt, Germany). All the chemical agents 
were analytic grade and used without further purification. It should be noted that no 
differences were found between the Sigma obtained ovalbumin and the self purified native 
ovalbumin. For model polymeric studies we used three short homopolymers: lyophilised 
native ovalbumin (45kDa), modified ovalbumin and drug conjugated ovalbumin.  
 
3.2.2. Methods: 
3.2.2.1. Purification and preparation of the native Quail hen eggs for analysis   
The purification method for native ovalbumin was adopted from literature for the purification 
of ovalbumin (Takahashi et al., 1996; Vachier et al., 1995). Briefly Quail hen eggs, 
lyophilised ovalbumin was prepared by treating ovalbumin with a solution of ammonium 
sulphate. The ovalbumin was then washed three times in deionised water and frozen to -
70°C and lyophilised for 24 hours. Native ovalbumin (OVA) was then stored at 25°C or at 
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room temperature until further analysis. Briefly 250mg of modified lyophilised ovalbumin was 
dissolved in 10mL of 100mM of dithiothreitol buffer solution and incubated for 4 hours. The 
reduced ovalbumin solution was then washed in deionised water and then stored at 2°C until 
further analysis 
 
3.2.2.2. Reduction of the disulphide bonds of the native ovalbumin into thiols 
100mM of dithiothreitol solution was prepared for ovalbumin disulphide (SS) modification.  
100mg of lyophilised ovalbumin powder was dissolved in 10mL of 100mM dithiothreitol 
solution and incubated for 4 hours. The polymer solution was then centrifuged and washed 
three times with deionised water, frozen at -70°C in a refrigetarator and lyophilised for 48 
hours. 
3.2.2.3. Characterization of the native ovalbumin and thiol modified ovalbumin  
The surfaces of the native disulphide ovalbumin and thiol modified ovalbumin were analyzed 
using the scanning electron microscope (SEM) (PHENOM™ Desktop SEM, FEI Company, 
Oregon, USA) operated at 10KV in the electron imaging mode. Briefly the ovalbumin 
samples were mounted on specimen stubs and gold coated using a SPI-ModuleTM sputter 
coater (SPI Supplies, STRUCTURE PROBE INC, West Chester, Pennsylvania, USA) and 
then observed at 600X magnification.  
 
3.2.2.4. Ultraviolet spectrophotometry for the determination of thiols 
Ovalbumin (0.2mg/mL) was incubated at 37°C for 125 minutes in Tris-EDTA buffer. 0.01 
volume of 0.4mMol dithio-bis nitrobenzoic acid was added to the sample. After 1 hour at 
room temperature the absorbance, at 413nm was measured and reactive thiols were 
determined on the basis of a molar extinction coefficient of 13,600 M-1/cm-1.  
 E =
A
bc
                                                                                                                              (1) 
Where A=absorbance, b= path length in centimetres, c=concentration in moles/litre (=M). 
 
3.2.2.5. Size and zeta-potential measurements of the native and modified ovalbumin  
The particle size and zeta-potential of the unmodified and thiol reduced ovalbumin were 
analyzed using the NanoZS instrument (Malvern Instruments (Pty) Ltd., Worcestershire, 
UK). Briefly, the ovalbumin solutions were dispersed in double distilled water, and filtered 
through the 0.22µm pore filter. The 10mm quartz cuvette containing the ovalbumin solutions 
were separately were analysed by filling the cuvette with 1mL of the filtered ovalbumin 
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solution. The zeta-potential was determined using a capillary cell after diluting the solution by 
a factor of 1:10.  
 
3.2.2.6. The conjugation of the modified thiol ovalbumin with thiol containing captopril  
Predetermined captopril, (50mg) was added to the 100 mM disulphide reduced ovalbumin 
solution and incubated for 1 hour for thiol-thiol binding saturation. The ovalbumin-captopril 
conjugate solution was then centrifuged and washed three times with deionised water, 
frozen at -70°C and lyophilised for 24 hours.  
 
3.2.2.7. UV analysis for the determination of the thiol concentrations  
Stock solutions were prepared by separately dissolving 10mg of Captopril HCl in 100mL of 
Phosphate Buffered Saline (PBS) (pH 6.8). From the stock solution a series of dilute 
standard solutions of the following concentrations: 0.125, 0.25, 0.50, 0.75, 1.0 and 1.25 
mg/mL were prepared. The absorbance of each standard solution was determined at the 
maximum wavelength of absorption (λmax) of 271nm for captopril hydrochloride. 
 
3.2.2.8. UV analysis of the ovalbumin-captopril complex 
Ovalbumin protein, (100mg) was incubated with 50mg captopril for 24 hours at room 
temperature. Quantification of captopril was achieved via spectrophotometry at 271nm (Cecil 
CE 3021, 3000 Series, Cecil Instruments, Cambridge, England). The conjugation efficiency 
of the OVA-captopril conjugates was calculated using the following equations: 
 
Conjugation efficiency (%) =   
weight of drug found conjugated 
weight of total drug used
 X 100                                     (2) 
                                                             
Drug content (%w/w) = 
weight of drug conjugated
weight of conjugate
  X 100                                                           (3) 
 
 
3.2.2.9. ATR-FTIR analysis of the native, thiol and ovalbumin-captopril  
Attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR) is used to 
study molecular surface interactions.  It is an advantage in the analyses of a whole IR 
spectrum, especially in mid-IR region where the molecular-specific fingerprint region occurs. 
The powdered samples of the three ovalbumin variants, namely native, thiol modified and 
captopril conjugate complex of ovalbumin were analysed using the the Perkin Elmer 2000 
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FTIR spectrometer that was fitted with a MIRTGS detector (PerkinElmer Spectrum 100, 
Llantrisant, Wales, UK). The three ovalbumin variants were analyzed at a wavelength 
number of 650-4000cm-1 with a resolution of 4cm−1. The absorbance was also measured at 
a wavelength number of 0-0.75nm. 
 
3.2.2.10. H+ NMR analysis of the native and thiol modified ovalbumin  
Thiol functional groups bind readily to metal ions and form hydrogen bonds, which stabilize 
the secondary and tertiary structures of proteins [detection of sulfhydryl groups 3,4]. The 
unique feature of thiol groups is their low proton/deuteron fractionation factors (SD/SH=0.5), 
making thiols of cysteine residues to preferentially bind to protons, rather than deuterons in a 
ymixture of water and deuterated water. 
 
3.2.2.11. Rheological analysis of the native, thiol and ovalbumin-captopril 
The viscosity (ƞ), storage and loss modulus (G’and G” respectively) were analysed using the 
modular advanced rheometer (HAAKE MARS Modular Advanced Rheometer, Thermo 
electron Corporation, Karlsure, Germany). The native, thiol modified and captopril 
conjugated aqueous samples were measured at different sampling points to assess the 
rheological changes affecting inter and intramolecular changes that occurred during 
analysis. All samples were analysed at room temperature except for the thermal analysis 
response of the samples at high temperatures of 90°C summary the sample solution was 
poured onto the parallel-plate geometry (50 mm in diameter) and a small amount of silicone 
oil was applied at the periphery of the solution to prevent evaporation. The dynamic storage 
modulus (G’) and loss modulus (G”) were examined as functions of temperature. The 
specific viscosity of ovalbumin solutions (100mg/mL 20mM phosphate buffer, pH 7.0, 
containing  0.1 M NaCl, filtered through a 0.45µm filter) that had been subjected to 1 hour at 
37°C and cooled at 25°C. The Haake viscometer was calibrated with the ovalbumin solution 
before heating. 
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Fig.3.1.1. Image of the captopril conjugated ovalbumin which was placed between the two 
parallel plates for rheological analysis. 
 
3.2.2.11.1. Yield stress test of the native, thiol and ovalbumin-captopril 
5mL of aqueous ovalbumin solutions, namely native, thiol modified and captopril conjugated 
ovalbumin was placed between the two parallel plates (Figure 3.1.1). To prevent 
evaporation, silicon oil was added to the ovalbumin solution to seal it. Since the silicon oil 
was non–reactive under experimental conditions, its viscosity would not change with 
temperature during measurement. The sealed fixture was then covered with a conical silicon 
cover to mitigate solvent evaporation and ensured uniform temperature distribution.  
 
3.2.2.11.2. Viscosity of the native, thiol and ovalbumin-captopril 
Viscosity was analysed to determine the resistance to flow of the native, thiol modified and 
captopril conjugated ovalbumin in aqueous solution. The samples were subject to a shear 
rate range of 0 – 200 1/s over 180 seconds. 
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3.2.2.11.3. Oscillatory stress sweep of the native, thiol and ovalbumin-captopril 
The analysis of the viscosity and elastic behaviour of the native, thiol modified and captopril 
conjugated ovalbumin aqueous solutions and the network structure formed by drug/particle-
particle interactions, an oscillation frequency sweep test was performed. Oscillation stress 
sweep tests were carried out at a constant frequency of 1Hz in a stress range of 100 Pa. 
Oscillation frequency sweep tests were performed over a frequency range from 0.1 to 10 Hz 
at constant stress amplitude of 1 and 5 Pa, respectively. 
 
3.2.2.11.4. Oscillatory frequency sweep of the native, thiol and ovalbumin-captopril 
A frequency sweep test is a dynamic test measuring the response of a system as a function 
of frequency at constant stress amplitude. It demonstrated that the storage modulus G’ 
(elastic response), the loss modulus G” (viscous response) and the complex viscosity of a 
sample. The shear stress of each sample was dependant on the on the yield value obtained 
from the yield stress measured. 
 
3.2.2.11.5. Oscillatory thermal analysis of the native, thiol and ovalbumin-captopril 
The linear viscoelastic region of the systems was first determined the oscillatory stress 
sweep. Temperature ramps were performed over the range 20–90 ◦C, at a frequency of 1 
Hz, with an oscillatory torque of 500 Nm. During the frequency sweep, a solvent trap 
polycarbonate cover was used to prevent sample drying and evaporating as this would affect 
the rheological properties of the ovalbumin solutions. 
 
3.2.2.11.6. Thermal characterization of the native, thiol and ovalbumin-captopril 
The thermal characterisation of the native, thiol modified and captopril conjugated ovalbumin 
were performed on a Differential Scanning Calorimetry (DSC) (1 STARe system, Mettler 
Toledo, Schwerzenbenbach, Switzerland). 50mg/ml of native ovalbumin, modified ovalbumin 
and captopril-SS-ovalbumin were heated from 25 to 100°C at 1 °C/min. The denaturation 
temperature (Td) was evaluated using STARe software. The total enthalpy change and the 
enthalpy changes of the polymers and drug were determined by integration of the peak area 
upon deconvolution of the recorded thermogram of the three native, thiol modified and 
captopril conjugated components. 
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3.3. Results and Discussion 
 
3.3.1. Morphological characterization of the disulphide native ovalbumin polymer 
Ovalbumin proteins undergo significant conformational changes, when subjected to extreme 
pH conditions which in turn affect the structural integrity and biological activity. These 
proteins, molten globule, maintain a relatively compact structure i.e., preserve most of 
secondary structure but lose some of their tertiary structure. Molten globule by definition is 
an ensemble of structure related molecules that are rapidly interconverging, but slowly 
change into a single unique conformation which results in greater flexibility of the protein. It 
was demonstrated that incubation of lyophilised Quail egg ovalbumin (Figure 3.2.i) at 
extreme acidic pH, resulted in a molten globule state as visualised in Figure 3.2.ii. The 
conversion of ovalbumin molten globule to unfolded state was energetically small and rapid 
which was followed by the unfolded state. The end of the unfolded state was characterized 
by the decomposition of hydrogen, disulphide and electrostatic bonds. In the unfolded state 
ovalbumin showed greater flexibility and increased folding caused by the interconverging of 
hydrophobic bonds which resulted in the aggregation of ovalbumin [3]. 
 
       
Fig.3.2. (i) Surface analysis of the unmodified native lyophilised ovalbumin. (ii) Morphology 
of disulphide reduced ovalbumin yielding a smooth porous surface. 
 
3.3.2. Size and zeta-potential comparison of the ovalbumin polymer 
In comparison to the native ovalbumin which had an average particle size of 226.9nm, the 
sizes of the modified ovalbumin fragments were 6nm after a 4 hour of reducing treatment 
with dithiothreitol. The reduction of the ovalbumin protein was a time and concentration 
dependant reaction.  The predetermined optimal concentration of dithreitol chosen for this 
 i ii 
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specific study was 30mM which yielded the best total free and bound thiols in solution. An 
average of 0.264mM of 100mg was obtained which bound on 30mg of drug. The zeta 
potential, shown in Figure 3.3, was greater in native lyophilised ovalbumin than in modified 
lyophilised ovalbumin. This could be because of the greater hydrogen ion concentration in 
solution from the reduced disulphide bonds yielding a value of -10mV and the native 
ovalbumin yielded a value of -26mV.  
 
 
Fig.3.3. Zeta Potential of unmodified and thiol modified ovalbumin dispersed in deionised 
water measured by DLS:  ovalbumin-SS and ovalbumin-SH. 
3.3.3. ATR-FTIR spectroscopy of the native, thiol and ovalbumin-captopril 
The kinetic studies of reduction and oxidation processes by IR-spectroscopy are useful in 
determining the presence of disulfide and thiol functionalities. The IR spectra of SS 
ovalbumin, degraded ovalbumin, and cross-linked drug ovalbumin are shown in the traces in 
Figures 3.4 and 3.5. Figure 3.7. Illustrates the absorbance of the SS and SH of ovalbumin 
before and after reduction of the SS of ovalbumin. In the spectrum of unmodified ovalbumin 
(Figure 3.6), the vSS band at 513cm-1 are observed, indicating the existence of the SS 
bonds. After degradation, the bands disappeared and new bands at 2637cm-1 (vSH) are 
detected (Figure 3.6).  
              ovalbumin-SS                   ovalbumin-SH 
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These results reveal the degradation of the SS bond and the formation of SH groups (Alting 
et al., 2000; Alting et al., 2003). The results prove the cleavage and reformation of disulphide 
bonds in response to the redox conditions occurred. The absorbance of the modified 
ovalbumin at 2637cm-1 was 0.275. These results correspond to those reported by Pinhas-
Hamiel, (1996) and Lin et al. (2001). Fleming, (1989), reported that the S-H absorption as 
being typically weak and occurring at lower wavenumber (frequency) because of the higher 
atomic mass of sulphur, they also note that the k was smaller with a value of 340kJ mol-1. It 
should be noted however that the SH wavenumber is generally stronger when using Raman 
spectroscopy. The IR spectra also showed OH stretching at 3277.96cm-1, C-H 2987cm-1, C-
O at 174cm-1 3, C=C 1679cm-1, amide I and II at 1632cm-1, C=N at 1551cm-1, C-O of COO- 
at 142cm-1 4, -CH at 1387cm-1  and C-O-H stretching 1156cm-1.  
 
 
Fig.3.4. The IR spectra of captopril the versatile and reactive thiol group at 2566.66cm-1.  
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Fig.3.5. IR-spectroscopy showing the comparison of the native unmodified ovalbumin 
against the modified of ovalbumin-disulphides prepared in 20mM phosphate buffer. 
 
 
Fig.3.6. IR-spectroscopy of the thiol modified ovalbumin in comparison to the Captopril 
bound ovalbumin samples. 
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Fig.3.7. Spectra indicating the absorbance of modified ovalbumin and captopril bound 
ovalbumin samples were indicated. 
 
3.3.4. H1 NMR Spectrum 
The thiol concentration was determined directly to be 264 µmol/100g. The conversion of 
ovalbumin to ovalbumin-thiol would result in 528µmol/g of thiol concentrate. The resultant 
structure was analyzed by NMR. In the 1H NMR two types of stabilizing thiols were found in 
the ovalbumin structure after modification with dithiothreitol. The expected surface dithiols 
with protected ω-thiol functionality were detected and the linked dithiols could also be found. 
The combination of the two dithiols provided ovalbumin with increased stability. The 
destabilisation of ovalbumin caused by the disintegration of disulphide bridge resulted in the 
formation of linked dithiols. In Figure 3.8, represented (i) pure captopril and (ii) the 
dithiothreitol modified ovalbumin containing free thiol motifs and (iii) the ovalbumin-captopril 
conjugate complex. There are definite peaks in Figure 3.8 (i) that are not present in Figure 
3.8 (ii and iii). There were free thiols with thiol functionality and double surface linked thiols. 
The broadness of the signal signified the restriction of mobility of the double linked thiols and 
the narrow signals were the easily accessible thiols (Masihul et al., 2002).  
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                                                 iii. 
 
Fig.3.8. 1H NMR Spectrum of (i) Captopril (ii) modified ovalbumin containing free thiol motifs 
and (iii) ovalbumin-captopril conjugate in 100% deuterated CdCl3. 
 
i.                                                                          ii. 
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3.3.5. Conjugation efficiency and drug content 
In polymer conjugation, two necessities that are required for click chemistry based on the 
philosophy can be defined, for which polymer reactions must be tested to assess their ability 
for practicable modular transformations: (i) end group alteration without any presence of 
reduced side products and (ii) high conjugation efficiency when at least two 
polymer/molecules are coupled to each other, and that the completion of the reaction on a 
equitable time scale without using an excess of one reaction polymer (Madurai et al., 2011; 
Kim et al., 2008). The violation of any of the above two requirements would ultimately lead to 
complex product combinations that in the worst case are non-separable. The drug 
conjugation efficiency of ovalbumin and captopril measured was 79%. The thiol 
concentration was extrapolated from the L-cysteine calibration curve which had a correlation 
coefficient of R2=0.99, (Fig.3.9). The conversion of disulphides to thiols when treated with 
dithiothreitol, were shown in Fig.3.10. The conversion was a linear relationship, i.e. with 
increasing thiol concentration was a direct decrease in the disulphide bond concentration.  
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Fig. 3.9. Calibration curve for L-lysine cysteine for thiol quantification.  
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Fig.3.10. Thiol conversion from the unmodified ovalbumin into the reduced thiol groups 
treated with dithiothreitol. 
 
3.3.6. Thermal analysis of the variant ovalbumin complex 
Pharmaceutical compounds exhibit polymorphic characteristics that influence stability and 
bioavailibility. The glass transition (Tg) is an important parameter in characterizing 
pharmaceutical compounds (Hornof et al., 2003; Sachan et al., 2012). The glass transition 
(Tg) of ovalbumin was 72.25°C, Fig 3.11, which corresponded to the glass temperature 
range reported by Cramer et al., (2004) of about 75.0°C. The degree of crystallisation or 
immobilisation of the ovalbumin protein was due to other interactions that affect stabilisation 
of the secondary ordered structures. Covalent crosslinkages between disulphide bonds and 
other interchain interactions called hyper tanglements (Fergusan et al., 1980) contributed 
directly to the increase of glass transition (Figure 3.11). These included the van der Waals, 
hydrophobic, and electrostatic interactions, and hydrogen bonds which were disrupted by the 
increase in heat, resulting in a shift of the glass transtion. It was evident that as the glass 
transition temperature was increased, the crosslink’s between the disulphide bonds were 
reduced in size and width, thus directly increasing the viscosity.  
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Fig.3.11. Comparative thermogram illustrating the change in the glass transition 
temperatures of pure unmodified ovalbumin at 72.25°C and Cp-Ovalbumin was measured 
as 90.15°C. 
3.3.7. Thermal characterization of the native ovalbumin and its conjugate 
In order to further identify the different thermal transitions observed, temperature modulated 
differential scanning calorimetry was employed. In this specific modulation technique, the 
total heat flow was measured. The non-reversing heat flow was the difference of the total 
heat flow and the reversing heat flow. In Figure 3.12.i. the three heat flows of the ovalbumin 
polymer were separate, symbolising the polymer in its native state under quasi-isothermal 
conditions.  
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Fig.3.12.i. Non-reversing and reversing heat flows derived from the ADSC of (A) unhydrated 
native ovalbumin. 
On modification of ovalbumin by addition of the pharmaceutical compound captopril the non-
reversing heat flow increased, because of the disruption within the polymer associated with 
the exposure of the thiol groups, (Figure 3.12.ii). 
 
Fig.3.12.ii. Non-reversing and reversing heat flows derived from the ADSC of (B) the 
conjugate captopril to ovalbuminIn. iii. The total heat flow remained constant but there was 
an overlap between the non- and reversing heat flows, because of the addition of the high 
crystalline structure captopril. The overlap was an indicator of glass transition and 
crystallization. 
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Fig.3.12.iii. Non-reversing and reversing heat flows derived from the ADSC of (C) thiol 
modified ovalbumin. 
 
Up to a temperature of about 40°C the ovalbumin solutions were fluid, with a viscosity of 
minmum 72.9Pa s. During this heating phase the properties of the solution did not change, it 
is believed that the protein retained its native, folded structure (Liu et al., 2006)  However 
when the temperature reached about 40-60°C, small white precipitates appeared which 
indicate the definite change in the protein structure. The heating of the ovalbumin solution to 
77°C lead to secondary thermal transitions, thus increasing the viscosity. The region was 
identified as the irreversible denaturation of the ovalbumin solution. By fitting it in a linear 
background slope of the curve before and after the thermal transition, the melting 
temperature (Tm) was determined for the ovalbumin solution. This value corresponded to 
the melting temperature recorded by the differential scanning calorimetry. The viscosity 
continued to increase beyond 74°C, saturating around 79-80°C before diminishing slightly at 
greater temperatures. Upon cooling the viscosity increased but never recovered confirming 
the proteins irreversible denaturation.  
 
When the protein macromolecules in solution were heated, the weaker bonds between the 
amino acids holding the tertiary folded structure were the first to disintegrate. As the 
structure deformed the internal functional groups specifically the thiol groups were exposed 
to the buffer solution and began to form bonds with ions and water, forming new hydrogen 
bonds in the peptide structure of ovalbumin. Additional rebinding within ovalbumin by 
interverconging hydrogen, disulphide and electrostatic bonds had formed, which resulted in 
the formation of aggregated ovalbumin microstructures. This unfolding and the subsequent 
disulphide interactions affected the ovalbumin solution’s viscosity thereby changing the 
ovalbumin protein’s rheological properties around melting temperature. Disulphide bonds 
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directly affected the mechanical properties (viscosity, tensile, strength, hardness) of 
ovabumin and were correlated to the degree of disulphide bonding. 
 
Slow decomposition of ovalbumin began at 200°C and accelerated the 245°C. The 
conjugate complex ovalbumin and captopril started to decompose vigorously at 245°C (data 
not shown). The ovalbumin-captopril complex contained more water molecules that were 
strongly conjugated than ovalbumin at 18°C and 7°C, respectively. The peaks of the 
evolution of absorbed water appeared in the thermograms at 62°C and 53°C respectively. 
Regardless of their composition their relatively fast decomposition began at 200°C and 
proceeded slightly more readily for complexes with excess of the ovalbumin-captopril 
complex, whereas the complex with excess of ovalbumin decomposed more slowly.  
3.3.8. Rheological analysis of the ovalbumin complex  
In general, the viscoelasticity of a protein or colloidal solution is a manifestation of both the 
increased resistance to flow that originates from the friction experienced by the dispersed 
moieties, and from the strength of interactions that must be overcome to cause any 
deformation from an undisturbed state. The degree of crosslinking correlates to the increase 
in yield stress and the extension of the visco-elastic region.  
 
3.3.8.1. Oscillation stress sweep 
Interfacial shear rheology provides a sensitive tool to study aging kinetics, which can be 
affected by numerous parameters such as diffusion and adsorption behaviour, 
rearrangement, physical gelation, secondary adsorption and S-H to S-S exchange in 
ovalbumin molecules. To get comprehensive information on the rheological state of the 
formulation, oscillation measurements yielding information about viscosity and elastic 
properties of the investigated system were performed. Oscillation tests are dynamic methods 
for determining the viscoelastic properties of the tested material in its rheological ground 
state. When determining the oscillation measurements of a solid formulation, the viscoelastic 
region must be measured first by a stress sweep at constant frequency. By definition, a 
stress sweep test is a test where the complex modulus G’ is measured as a function of 
stress at a constant frequency. The range of stress over which G’ is independent of the 
applied stress is called the linear viscoelastic region. Over the linear region, the complex 
structures of the macromolecules remain intact, despite them displaying different 
behavioural patterns. A value of 1 Pa was chosen as the stress amplitude in the subsequent 
studies since it lies in the viscoelastic region for both tested systems. A decrease of the 
elastic modulus was indicative of the viscoelastic. In Figure 3.13 was evident that as the 
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elastic modulus increased, deformation was reduced. The elastic moduli of the drug 
conjugated ovalbumin were higher than the native and modified ovalbumin. The addition of a 
bioactive such as captopril enforced the intermolecular forces between ovalbumin and 
captopril, also reinforcing the S-S bond between the two components. The increased 
breaking point of the drug conjugated ovalbumin may have been due to the interchange of 
S-H and S-S bonds between ovalbumin and captopril according to Erni et al.2006. The 
breaking point was marked by the saturation of the intermolecular bonds, including the S-S 
bonds, resulting in deformation.  
 
 
Fig.3.13. Elastic modulus (G’) as a function of temperature ramp (˚C) for the native 
polymers. Povalbumin (native ovalbumin). Cp-ovalbumin (captopril bound ovalbumin). 
Movalbumin (thiol modified ovalbumin). 
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3.3.8.2. Frequency sweep 
The elastic and viscous contributions to the interfacial shear modulus are shown by filled and 
hollow symbols respectively in Figure 3.14. At low frequencies the interface response was 
dominated by high viscous effects and G’ was greater than G”. There was no crossover 
between G’ and G” for the native polymer, G1 and G2. The crossover frequency ω 
decreased and the corresponding modulus values also decreased with increasing time. The 
crossover of the frequency occurred at very low frequencies for the modified (G3 and G4) 
and for captopril bound ovalbumin (G5 and G6). The lower crossover frequency observed at 
higher bulk concentrations corresponds to a longer relaxation time period, implying that the 
interface had larger aggregates or was a more compactly packed protein [rheology]. Intially 
G3-G6 was more viscous before the crossover, and after the crossover was more elastic. 
This indicated that G3-G4 behaved in a solid-like manner instead of a gas or liquid manner. 
The native and modified ovalbumin behaved more elastic as the G’ was greater than the G”, 
whereas the captopril conjugated ovalbumin was more viscous because G” was greater than 
G’ for the remainder of the test. On the contrary, the G1 and G2 were parallel. The elastic 
moduli were greater than the loss moduli, signifying the undeformed state of the polymer, as 
the structure was uninterrupted.     
 
 
Fig.3.14. Frequency sweep showing storage (G”) and loss (G‘) modulus (Pa) versus time 
segment (s). G1 (○), G2 (●), G3 (∆), G4 (▲) G5 (□) and G6 (■). 
58 
 
3.3.8.3. Oscillation stress sweep 
Interfacial shear rheology provides a sensitive tool to study aging kinetics, which can be 
affected by numerous parameters such as diffusion and adsorption behaviour, 
rearrangement, physical gelation, secondary adsorption and S-H to S-S exchange in protein 
molecules. To get comprehensive information on the rheological state of the formulation, 
oscillation measurements yielding information about viscous and elastic properties of the 
investigated system were performed. Oscillation tests are dynamic methods for determining 
the viscoelastic properties of the tested material in its rheological ground state. When 
determining the oscillation measurements of a solid formulation, the viscoelastic region must 
be measured first by a stress sweep at constant frequency. By definition, a stress sweep test 
is a test where the complex modulus G’ is measured as a function of stress at a constant 
frequency. The range of stress over which G’ is independent of the applied stress is called 
the linear viscoelastic region. Over the linear region, the complex structures of the 
macromolecules remain intact, despite them displaying different behavioural patterns. A 
value of 1Pa was chosen as the stress amplitude in the subsequent studies since it lies in 
the viscoelastic region for both tested systems. A decrease of the elastic modulus was 
indicative of the viscoelastic. In Figure 3.15 was evident that as the elastic modulus 
increased, deformation was reduced. The elastic modulus of the drug conjugated ovalbumin 
was higher than the native and modified ovalbumin. The addition of a bioactive such as 
captopril enforced the intermolecular forces between ovalbumin and captopril, also 
reinforcing the S-S bond between the two components. The increased breaking point of the 
drug conjugated ovalbumin may have been due to the interchange of S-H and S-S bonds 
between ovalbumin and captopril according to Erni et al., (2006). The breaking point was 
marked by the saturation of the intermolecular bonds, including the S-S bonds, resulting in 
deformation.  
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Fig.3.15. Elastic modulus (G’) as a function of time (sec) for the polymers. Pure native (□) 
ovalbumin, ovalbumin-captopril (∆), thiol modified ovalbumin (X).  
 
3.3.8.4. Physicomechanical properties of ovalbumin 
The viscosity of native ovalbumin was 72.9 ± 0.74Pa.s. The increase in viscosity of the 
modified ovalbumin-SH was due to the intermolecular creation of disulphide bonds. It was 
also noticed that the viscosity of the modified ovalbumin was time dependant, with increased 
ovalbumin-SS bond formation. These results verify the existence of intermolecular sulphide 
bridges between ovalbumin thiols and the captopril thiols. To quantify the viscosity of 
ovalbumin-captopril and confirm the increase in viscosity rheology experiments were 
performed and confirmed the increase in viscosity of 182.8±26.83Pa.s.  
A direct correlation existed between the decreases in the number of thiols against the 
increase in viscosity. Thiolated polymers are capable of providing comparatively more 
pronounced increase in viscosity, as extensive crosslinking occurs due to the formation of 
disulfide bonds between the polymer chains (Fleming et al., 1989). In the modified 
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ovalbumin as the number of thiol groups decreased there was an increase in the viscosity of 
the ovalbumin solution. This was caused by the increase in the formation of inter- disulphide 
bonds as previously stated. The reduction of disulphide bonds caused a reduction in the 
secondary structure of ovalbumin, which resulted in a reduction of the stabilizing bonds 
within ovalbumin (Bernkop-Schnurch et al., 2003). 
 
3.4. Concluding Remarks  
Thiol functional groups play an important role in stabilising and solubilising proteins in 
aqueous solutions. The reaction of the thiol groups lead to physical and chemical 
conformational changes which directly affect the bond formed.  The successful conjugation 
of free thiol groups provides a versatile tool for functionalizing proteins for protein and thiol-
containing bioactives. This research demonstrates how the role of thiol and disulphide 
chemistry in proteins such as ovalbumin may lead to new methods being employed in 
formulating thiol based pharmaceuticals. 
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CHAPTER 4 
Sustained Delivery of Captopril from Ovalbumin Particles 
 
4.1. Introduction 
Captopril (Cp; 1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline), is an orally administered 
active angiotensin-converting enzyme (ACE) inhibitor used worldwide as an effective 
treatment of hypertension and congestive heart failure (Seta et al., 1988; Boomsma etal, 
1981; Volland et al., 1994). It is metabolised into the n-carboxyl derivative in the liver and 
excreted mainly in the urine (Duchin et al., 1988). It has been reported that a single dose of 
captopril can regulate hypertension for up to eight hours and the duration of the 
antihypertensive action of a single dose of 35-75 mg would be taken at 8 hour intervals for 
24 hours (Khalil et al., 2001; Darren et al., 2009). Hence the necessities in developing 
controlled release formulations to maintain relatively constant blood pressure levels for 
longer periods of time. Captopril contains a reactive thiol group, which binds onto the zinc 
ion of the angiotensin converting enzyme thereby inhibiting activity of the enzyme (Singhvi et 
al., 1982).  
The binding of Zn2+ onto the enzyme results in the formation of disulphide linkages with 
plasma proteins (Mandel et al., 2011) but also results in the formation of disulphide dimers of 
captopril, captopril-cysteines and relative endogenous thiol containing compounds (Miazaki 
et al., 1982). A number of drug delivery systems have been designed to sustain the release 
of captopril; these include microcapsules (Andreoli et al., 1993), floating tablets (Bagchi et 
al., 1989), bioadhesive polymers (Antonaccio et al., 1982), pulsatile delivery systems 
(Rezende et al., 2007), hydrophobic tablets (Singjh et al., 1988), semisolid matrix systems 
(Matharu et al., 1992) and coated tablet (De Crosta et al., 1987). 
Pharmeceutical research has been aimed at reducing the problems with not only 
conventional drug delivery systems but also with drug delivery systems that require 
biocompatible and stable drug delivery systems for molecules. The preparation of the 
hydrogels directly affects the bioavailability of the drug by protecting and supporting the 
process of site specific targeting of the drug delivery system. Hydrogels have been used 
widely in the development of biocompatible and bioavailable biomaterials due to their low 
interfacial tension and frictionless surface in the presence of an aqueous medium. 
Chemically hydrogels are cross-linked to each other by covalent bonds, and thus, the 
hydrogel is one molecule regardless of its size. Hydrogels have similar physical properties 
as that of living tissue, and this similarity is due to the high water content, soft and rubbery 
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consistency, and low interfacial tension with water or biological fluids. Factors like polymer 
composition, water content, crosslinking, density, and crystallinity, can be used to control the 
release rate and release mechanism of bioactives from hydrogels (Wong et al., 1981). 
The ability of hydrogels to absorb water is due to the presence of hydrophilic functional 
groups such as the –OH, -CONH and the –COOH, which directly affect the swelling 
properties of hydrogels. Since hydrogels have high permeability for water soluble drugs and 
proteins, the most common drug release mechanism is through diffusion. Hydrogels affect 
properties such as the permeability, mechanical and surface properties as well as 
biocompatibility. Various factors can be used to control the release rate and drugs from the 
drug delivery systems but most important were factors such as the polymer composition, 
crosslinking, water content and crystallinity. Hydrogels are technically characterised in a 
number of ways, e.g. by SEM, XRD, in vitro diffraction, FTIR, swelling behaviour and 
rheology, to name a few. The challenge that has been associated with designing controlled 
drug release systems for captopril has been in the instability of the drug in vivo (Soares et 
al., 2004).  
The success of an effective drug delivery system may be evaluated completely by stability 
studies. The sole purpose of stability testing is to obtain a stable product which maintains its 
efficacy to the maximum shelflife at specific storage conditions and maintain peak drug 
release profiles. The advantages of a stable formulation are: 
• Prolonged residence time at the site of action  
• Localization of dosage form at a specific site 
• Increased drug concentration gradient across the intestine, increasing contact of the 
drug particles with the mucosa 
• Direct contact with the intestinal cells, which preceeds particle absorption (Rashid et 
al., 1990). 
Captopril tends to have a burst phenomenon because of its high water solubility when 
formulated as a controlled or sustained release drug delivery system. In this chapter we 
utilise the openly vulnerable reactive thiol in captopril to bind to a protein that can act as a 
carrier thus stabilise captopril release in vivo and in vitro. Another important factor also 
contributing to the release of captopril is its solubility in an acidic environment. Due to its pKa 
of 3.7, captopril is highly soluble at pH 1.9 and has a half-life of 2 to 3 hour, it was necessary 
to develop a sustained drug delivery system. The prolonged captopril delivery system would 
have to increase the mucosal residence time, effectively control the release of the captopril 
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and improve its half-life of captopril, while providing better blood plasma stability 
concentration of captopril in vivo and in vitro. Only free captopril is pharmacologically active; 
hence the conjugation of the captopril to the ovalbumin vehicle carrier would have to be 
biocleavable. The disulfide derivative may act as a reservoir for free captopril and contribute 
to a longer duration of action than predicted by the blood concentrations of free captopril 
(Thakur et al., 1988). Captopril is rapidly and extensively metabolized in reactions involving 
its thiol group. The major metabolic pathway for captopril involves not only the formation of 
its disulfide dimer but also of mixed conjugates with endogenous thiol-containing compounds 
and plasma proteins (Wong et al., 1981). 
 
Investigations into polymers with various molecular characteristics have led to a number of 
inferences regarding the molecular characteristics required for mucoadhesion. The 
properties exhibited by a good mucoadhesive may be summerized as, (i) strong hydrogen 
bonding groups specifically the hydroxyl and carboxyle groups [-OH, -COOH]; (ii) strong 
anionic charges; (iii) sufficient flexibility to penetrate the mucus membranes or tissue 
crevices; (iv) surface tension characteristics suitable for the wetting mucus/mucosal tissue 
surface and lastly (v) high molecular weight (Bernkop et al., 2005). 
The interactions of different polymers such as natural or synthetic polymers play an 
important role in the release of a captopril. Cationic and anionic polymers bind more 
effectively than neutral polymers. Polyanions are better than polycations in terms of binding, 
and water soluble polymers give greater flexibility in the type of dosage forms compared with 
rapidly or slowly dissolving water-soluble polymers. Anionic polymers with sulphate groups 
bind more effectively than those with carboxylic groups. The degree of binding is 
proportional to the charge density on the polymer. The high binding hydrogels include 
sodium alginate, hydroxypropylmethylcellulose and polyvinyl alcohol. Table 1 includes a 
theoretical summary of the the three above mentioned hydrogels and their uses in 
pharmaceutical drug delivery systems. 
The aim of the chapter is to examine the pharmacokinetics of three main hydrogel polymers 
known for their controlled release properties namely, sodium alginate, 2-hydroxy propyl 
methyl cellulose and poly vinyl alcohol. These above mentioned hydrogels also have 
bioadhesive properties that could potentially increase the release of the captopril from the 
ovalbumin vehicle carrier system across the intestinal mucosa.  The aim would also provide 
a comparative of the three hydrogels and the formation of the most suitable nanoprticles for 
the release of captopril.  
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Table 4.1: Hydrogels and their intended application. 
Chemical Structure Co-polymer                      Application 
(C6H7NaO6)n Sodium Alginate Biodegradation, 
adhesiveness, Thermo and pH 
sensitivity 
Gelling, thickening  
and stabilizing applications 
binding agents in tablets, 
Targeting to mucosal tissues 
Slow release applications 
[CH2CH(OH)]n Polyvinyl (alcohol) Adhesiveness, 
Biodegradadtion 
Gelling,  
Controlled release systems  
Thermo sensitive 
C56H108O30 Hydroxypropylmethylcellulose Gelling, Thickening  
Adhesiveness 
 
4.2. Materials and Methods 
4.2.1. Materials 
Purified lyophilised ovalbumin (OVA), Dithiothreitol (DTT), 2-Mercaptoethanol (2-ME) and 
captopril were purchased from Sigma (Sigma Aldrich, Missouri, USA). Ethanol, Sodium 
Alginate, Polyvinyl (alcohol), Hydroxypropylmethylcellulose, Potassium phosphate 
monobasic and Disodium hydrogen phosphate were purchased from Merck (Merck KGaA, 
Darmstadt, Germany). All the chemical agents were analytic grade and used without further 
purification 
4.2.2. Preparation of the disulphide ovalbumin conjugates 
As previously described in Section 3.2.2.4., predetermined 50mg of captopril was added to 
the 100mM reduced ovalbumin solution and incubated for 1 hour to ensure complete thiol-
thiol binding saturation. The ovalbumin-captopril conjugate solution was then centrifuged and 
washed three times with deionised water, frozen at -70°C and lyophilised for 24 hours.  
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4.2.3. Preparation of nanoparticles 
4.2.3.1. Synthesis of ovalbumin-captopril nanoparticles 
A concentration of 0.06w/v for the three hydrogels namely, sodium alginate, poly-vinyl alcohol 
and hydroxyl propylmethyl cellulose was kept constant for the comparable release of 
captopril from all formulations (Manjanna et al., 2013; Chitra et al., 2012). The ovalbumin-
captopril conjugate were encapsulated with sodium alginate (NaAlg), poly-vinyl alcohol 
(PVA) or hydroxypropylmethylcellulose (HPMC) using calcium chloride. Preparation for the 
nanoparticles was as follows: Three sets of hydrogel coatings were prepared using cation-
induced controlled gelification methods. In all hydrogel methods 5mL of 18mM CaCl2, as a 
crosslinker was added dropwise to 50mL hydrogel solutions while stirring. OVA-captopril 
solution (20mL) was injected into the hydrogel solution dropwise using a 20mL syringe while 
stirring. The resultant biopolymeric OVA-captopril hydrogel solutions were then agitated 
overnight on a magnetic stirrer (CNW 21-2 Homothermal, China) at room temperature. The 
polymeric solution was then pre-freezed at -70°C for 24 hours and lyophilized at 1.35mtorr 
for 24 hours. The three sets of hydrogels were prepared in a similar way with certain 
modifications to each hydrogel. The parameters and compositions of the hydrogel 
formulations were summarised in Table 4.2 and 4.3. Figure 4.1 illustrates the formulation 
method for the three hydrogel ovalbumin carrier systems. 
 
 
 
 
                      
                                                                                                                                                
                                                                                                                     
Fig.4.1. Summary of the formulation method of the ovalbumin captopril carrier hydrogel 
formulation. 
 
  
50mL polymer solution 
Oil phase constituents: 
Ovalbumin-captopril complex. 
 
 
  
50mL hydrogel aqueous solution 
Aqueous phase constitueints: 
Sodium alginate/polyvinyl-
alcohol/hydroxypropylmethylcellulose 
 
CaCl2 droplets injected into mixture 
Freezing for 24 hour and 
Lyophilisation for 24 hour 
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Table 4.2. Parameters for the formulation preparation. 
Parameter Settings Units 
Polymer to cross linker ratio 1:5  w/v 
Magnet speed  1000 rpm 
Ambient Temperature 25 °C 
 
4.2.4. ATR-FTIR spectroscopy of NaAlg, PVA, and HPMC 
FTIR spectra of dried samples were acquired on a Perkin Elmer Fourier Transform Infrared 
spectrophotometer (FTIR) (PerkinElmer 100, Beaconsfield, United Kingdom) at wavelengths 
of 400-4000 cm-1. The spectra were collected at a resolution of 4cm-1 with 150 scans per 
spectrum. A background spectrum was acquired and assigned for use on subsequent 
spectral acquisitions for each sample. 
 
4.2.5. Thermal characterization of NaAlg, PVA, and HPMC 
Differential Scanning Calorimetry (DSC) (1 STARe system, Mettler Toledo, 
Schwerzenbenbach, Switzerland) was used to thermally characterize the three formulations. 
50mg/mL of native ovalbumin, modified ovalbumin and drug-SS-ovalbumin were heated 
from 25 to 100°C at 1 k/min. The denaturation temperature (Td) was evaluated using STARe 
software. The total enthalpy change and the enthalpy changes of the individual components 
were determined by integration of the peak area upon deconvolution of the recorded 
thermogram of the three components.  
 
4.2.6. Drug encapsulation efficiency of NaAlg, PVA, and HPMC 
The drug encapsulation efficiency (DEE) was calculated using the following equation. 
   DEE = 
Mi-Md
Mi
×100%                                                                                                         (1)                                                                                                                                                                                                   
Where Mi is the initial amount of ovalbumin-captopril dissolved in the hydrogel solution and 
Md the amount of hydrogel mass measured in the gelling media (CaCl2
.2H2O solution). 
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4.2.7. Morphological characterization of the each NaAlg, PVA, and HPMC formulations 
The size and morphology of the nanoparticles was analysed using the Scanning Electron 
Microscope (Perkin Elmer, USA). To determine the mean size of the nanoparticles dynamic 
light scattering was used for zeta size determination (Perkin Elmer, UK). To prepare the 
samples for zeta size: 10mg of sample was dissolved into 10mL of 4.1 pH borate buffer and 
immediately analysed to prevent swelling of the nanoparticles. The experiments were carried 
out in triplicate. For the zeta potential, to determine the stability of the nanoparticle, the same 
procedure as above was followed.  
 
4.2.8. Weight Variation of the NaAlg, PVA, and HPMC hydrogel matrices 
Three capsules were randomly selected from each batch and indidvidually weighed. The 
average weight and standard deviation of the 3 capsules were calculated. The batch passes 
the test for weight variation if all three of the individual capsules were similar to the average 
weight measured. 
 
4.2.9. Size increase index of the NaAlg, PVA, and HPMC hydrogel matrices 
Swelling measurements were analysed directly using the zeta sizer (Perkin Elmer, UK) at 24 
hours. The extent of swelling can be measured in terms of % size increase gained by the 
capsule. The capsule was soaked in 6.8 pH buffer solution for 24 hours and removed from 
the solution and weighted using the zeta sizer. The size increase ratio Qs was calculated by 
the amount of absorb water and calculated using the following equation: 
Qs =
Ss-Sd
Sd
× 100                                                                       (2) 
Where Sd is the weight of the capsule dry state and Ss the weight in the capsule’s swollen 
state.  
4.2.10. Rheological analysis of the dry NaAlg, PVA, and HPMC hydrogel matrices 
The viscosity of the three sets of nanoparticles namely, sodium alginate, poly-vinyl alcohol 
(PVA) and hydroxypropylmethylcellulose (HPMC) hydrogel were measured using the Haake 
viscometer (USA). The specific viscosity of hydrogel solutions (100mg/ml 20mM phosphate 
buffer, pH 7.0, containing 0.1 M NaCl, filtered through a 0.45µm filter) was subject to 24 hour 
incubation at room temperature before viscosity measurements were implemented.  
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4.2.11. In vitro Drug release from the NaAlg, PVA, and HPMC hydrogel matrices 
The in vitro release experiments were performed in Simulated Intestinal Fluid (SIF) to 
compare the performance of the three ovalbumin-captopril hydrogel. Complete formulations 
of each set of the nanoparticles were accurately weighed and placed in 500mL of 
temperature 37°C glass, volumetric flasks containing 500mL of the Simulated Intestinal 
Fluid. 1mL samples were taken from the release medium at specific time intervals for a total 
of 24 hours and replaced by fresh 1ml SIF buffer solution. The separate drug release profiles 
were then analysed using the four pharmacokinetic equations. Sink conditions were 
maintained by replacing the withdrawn 2mL samples with freshly prepared simulated 
intestinal fluid at each sampling time. The concentration of the drug released was 
determined utilizing the Ultraviolet Spectrophotometer (Cecil CE 3021, 3000 Series, Cecil 
Instruments, Cambridge, England) at λ271nm. From this concentration value the actual 
amount of drug was then calculated. 
• Zero-order model 
Drug dissolution from dosage forms that do not disaggregate and release the drug slowly 
can be represented by the equation: 
 
Q0 n.Qt = K0t                                                                                                                        (3) 
Rearrangement of equation (3) yields equation (4): 
 
Qt = Q0 + K0t                                                                                                                        (4) 
 
Where Qt is the amount of drug dissolved in time t, Q0 is the initial amount of drug in the 
solution (most times, Q0 = 0) and K0 is the zero order release constant expressed in units of 
concentration/time. Values of 0.5<n<1 indicate non-Fick Ian or anomalous mechanism due 
to both diffusion and polymer chain relaxation. 
 
• First order model 
This model has also been used to describe absorption and/or elimination of some drugs, 
although it is difficult to conceptualize this mechanism on a theoretical basis. The release 
of the drug which followed first order kinetics can be expressed by the equation: 
dC
dt
 = -kc                                                                                                                                  (5) 
Where K is first order rate constant expressed in units of time-1.Equation (5) can be 
expressed as: log C = log C0 n Kt / 2.303 (6) where C0 is the initial concentration of drug, k is 
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the first order rate constant, and t is the time. The data obtained are plotted as log 
cumulative percentage of drug remaining vs. time which would yield a straight line with a 
slope of nK/2.303. 
 
• Higuchi model 
This model is based on the hypotheses that (i) initial drug concentration in the matrix is much 
higher than drug solubility; (ii) drug diffusion takes place only in one dimension (edge effect 
must be negligible); (iii) drug particles are much smaller than system thickness; (iv) matrix 
swelling and dissolution are negligible; (v) drug diffusivity is constant; and (vi) perfect sink 
conditions are always attained in the release environment. Accordingly, model expression is 
given by the equation: 
 
Ft = Q = A √D (2C.ñCs) Cs.t                                                                                                (6) 
 
Where Q is the amount of drug released in time t per unit area A, C is the drug initial 
concentration, Cs is the drug solubility in the matrix media and D is the diffusivity of the drug 
molecules (diffusion coefficient) in the matrix substance. 
 
• Korsmeyer-Peppas model 
Korsmeyer et al., (1983) derived a simple relationship which described drug release from a 
polymeric system equation: 
 
Mt / M∞ = Ktn                                                                                                                            (7) 
 
Where Mt / M∞ are a fraction of drug released at time t, k is the release rate constant and n 
is the release exponent. The n value is used to characterize different release for cylindrical 
shaped matrices. 
 
 
4.3. Results and Discussion 
4.3.1. Morphological studies of the NaAlg, PVA, and HPMC nanoparticles 
The surface morpohology of sodium alginate, polyvinyl alcohol and hydroxylmethylcellulose 
microgels containing the ovalbumin-captopril drug carrier system were analysed. The 
microgels for sodium alginate and hydroxypropylmethylcellulose were poly dispersed but the 
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polyvinyl alcohol microgels were embedded in the polyvinyl alcohol hydrogel. The microgels 
for sodium alginate were larger in size with an even surface whereas the surfaces polyvinyl 
alcohol and hydroxylmethylcellulose were smoother were the smallest in size, Figure 4.1.
                                                                                                              
                                         
Fig.4.1. The SEM images for (A) sodium alginate, (B) polyvinyl alcohol and (C) hydroxyl 
methylcellulose micro gels containing the ovalbumin-captopril drug carrier system. 
 
4.3.2. Size and swelling of the NaAlg, PVA, and HPMC particles 
The zeta potentials of the sodium alginate hydrogel was -25.5mV, -21.6mV and -24.7mV 
(Figure 4.3) for the hydroxyl methylcellulose and polyvinyl alcohol hydrogel nanoparticles 
respectively. In all samples the stability of the hydrogel nanoparticle showed good stability 
ranging between -20 to -30mV in an aqueous solution. The size distribution graphs of the 
hydrogel formulations are provided in Figure 4.4. Polyvinyl alcohol resulted in two peaks 
showing that the aggregation and coagulation of the particles. Sodium alginate and hydroxyl 
methylcellulose showed single peaks of average stable particles. It was however noteworthy 
C 
B A 
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that the hydrogel nanoparticles would aggregate over time due to slow coagulation or 
flocculation of the nanoparticles when suspended in a flowing medium. The swelling results 
were summarised in (Table 4.4) with sodium alginate showing the highest swelling 
percentage, followed by polyvinyl alcohol and hydroxyl methylcellulose. These results show 
no statistical significance p<0.05. The swelling percentage showed 83-85% increase in mass 
of the hydrogel formulations. There was no statistical significant difference between the 
formulations. 
 
Fig. 4.2. The graphs represent the comparative size and zeta-potential values of the three 
particles. 1- Polyvinyl alcohol, 2- hydroxyl methylcellulose, and 3- sodium alginate. 
 
Table 4.4. Average size distribution of the hydrogel nanoparticles before and after swelling 
of nanoparticles. 
Sample Initial Size (nm) 
 
After swelling (nm) 
 
Swelling (%) 
 
PVA 
 
132.8±5.8 
 
817±23.3 
 
83.83% 
 
HPMC 
 
109.4±6.9 
 
649±28.9 
 
83.17% 
 
NaAlg 201.5±17.6 1363±33.7 85.22% 
 
132.8 
109.4 
201.5 
24.7 
21.6 
25.5 
1 2 3
Zeta-potential (-Vm) 
Size (nm) 
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Fig. 4.3. Size distribution graphs of the three Nano gel systems formed, namely, 1- polyvinyl 
alcohol, 2- hydroxyl methylcellulose, and 3- sodium alginate. 
 
4.3.3. IR spectra for the NaAlg, PVA, and HPMC nanoparticles 
The IR spectra for the native ovalbumin polymer and captopril and the conjugate complex 
ovalbumin-captopril were shown in Chapter 3, Section 3.3.2. The spectra for the three 
hydrogel formulations were similar, with some noted differences. Figure 4 shows all three 
spectra highlighted stretching of the OH grouping at 3281-3279cm-1, CH stretching at 2910-
2927cm-1, and COO stretching at 1732-1631cm-1. Amide I and II stretch at 1534 cm-1. The 
ovalbumin drug carriers system was a multiple-component delivery system achieved by multi 
crosslinking processes. The spectrum was different from the individual components, (spectra 
not shown). Some peaks were diminished and some new peaks were visible. The system 
contained possible alkyl, carbonyl and aliphatic esters, which explain the peaks at 3281cm-1 
to 667cm-1. The alkyl groups may be found at 3281cm-1, 3244cm-1, 1419cm-1. The carbonyl 
groups were visible at 1619cm-1, 1631cm-1 and 822cm-1. The aliphatic groups were visible at 
770cm-10 and 667cm-1.  
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Fig.4.5. Spectra for sodium alginate captopril bound nanoparticles, polyvinyl alcohol bound 
nanoparticles and hydroxy propylmethyl cellulose bound nanoparticles.  
 
4.3.4. Thermal analysis of the NaAlg, PVA, and HPMC nanoparticles 
As a powerful analytical tool, differential scanning calorimetry is capable of elucidating the 
factors that contribute to the folding and stability of biomolecules. The thermograms for the 
three hydrogel compositions are shown in Figure 4.6. The glass transition of hydroxy 
propylmethyl particles showed the thermal decomposition at a higher temperature of 183°C 
whereas the thermal decompositions of sodium alginate and polyvinyl alcohol where lower at 
40 and midway 115°C respectively. The glass transition temperature for native sodium 
alginate was reported to be 220°C (Zhang et al., 2009), which affected the increased Tg of 
the nanoparticles. The combination of the sodium alginate with a lower Tg polymer such as 
ovalbumin resulted in a shift to a lower temperature. The Tg temperature for the polyvinyl 
alcohol polymer was reported to be 85-89°C and that of hydroxy propylmethyl as 210°C 
(Guiguis et al., 2012). Polyvinyl alcohol nanoparticles demonstrated the most decrease in 
the thermal decomposition of the particles. Table 4.5 provided a summary of the thermal 
changes of the three hydrogel formulations.  
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 Fig.4.6. DSC Thermograms for the (a) sodium alginate, (b) polyvinyl alcohol, (c) hydroxyl 
methylcellulose hydrogel composites. 
 
Table 4.5.Summary table for the thermal characterization of the three hydrogel composites. 
                                                     At glass phase transition (%) 
Hydrogel composites                                   Tg (°C)                H (J/g)      
sodium alginate/ovalbumin                              43                     16557.15 
polyvinyl alcohol /ovalbumin                           115                    1753.56 
Hydroxypropylmethyl/ovalbumin                     182                   1895.20 
 
4.3.5. Newtonian Flow model for the NaAlg, PVA, and HPMC nanoparticles 
The Newtonian Flow model of fluids demonstrates a linear relationship that exists between 
shear stress and shear rate, where the coefficient of viscosity is the constant of 
proportionality. The laminar flow that is not characterized by a linear relationship between 
shear stress and shear rate is called non-Newtonian. Figure 4.7 demonstrated a linear flow 
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graph of the three hydrogel formulations. The yield flow analysis showed that the 
intermolecular forces within the structures caused conformational deformation within the 
strands, resulting in the hyper entanglements in the hydrogel structure. The entanglements 
in the hydrogel structures were enforced and caused shear thickening (T1-3), where T1, 2 
and 3 lay in a straight line. 
 
Fig.4.7. Characterisation of viscoelastic particles flow based on the Newtonian and non- 
Newtonian flow. T1-3 (x). 
 
4.3.6. Captopril release of the NaAlg, PVA, and HPMC nanoparticles 
Figure 4.9.depicts the difference in the cumulative drug release profiles of the three 
comparative formulations. The highest fractional drug release percentage at 24 hours was 
achieved by sodium alginate 78%, and then followed by polyvinyl alcohol at 61%, and last by 
hydroxy propylmethyl cellulose 40%. These results could be because of the influence of 
kosmotropic anions, according to Hofmeister series (Wang et al., 1999; Xing et al., 2003) 
which directly influence hydrogen bonding within the hydrogel matrix. Due to the small radius 
and the large charge density of the chloride ion, it had the strongest ability to compete for 
water molecules and form hydrogen bonds with other water molecules, which minimized or 
weakened the water-polymer hydrogen bonding. This in turn could have minimized the 
hydroxypropylmethyl and polyvinyl alcohol hydrogen bonding with water which ultimately led 
to a reduced amount of captopril being released (Leuner et al., 2000). Amidon provided an 
76 
 
alternative explanation that the ions disrupt the hydration process at the water-solute 
interface (Amidon et al., 1995). The concentrations were extrapolated from the calibration 
curve from Figure 4.8. 
Fig.4.8. Calibration curve of captopril in simulated intestinal fluid. 
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 Fig.4.9. Comparative drug release profiles of the three hydrogel composites. 
 
4.3.7. Release order analysis of the NaAlg, PVA, and HPMC nanoparticles 
The drug-release data were fitted to various kinetic equations to evaluate the drug release 
mechanism and kinetics. Regression coefficients (R2) were obtained from zero-order, first 
order, Higuchi model and the Korsmeyers coefficient-Peppas equations. The best fit with the 
highest correlation was shown in the first-order and the Korsmeyer-Peppas model, followed 
by the Higuchi model and lastly the zero-order as shown in Table 4.6. The Korsmeyer-
Peppas model was used to determine the n-value, which described the drug release 
mechanism. According to this model, the n-value was less than the 0.45 for the 
hydroxypropylmethyl cellulose and polyvinyl alcohol particles, which was indicative of Fick 
Ian diffusion. Fick Ian diffusion release occurred by molecular diffusion due to the chemical 
potential gradients in pH 6.8 media. The Fick Ian diffusion was higher than 0.45 for sodium 
alginate which was indicative of non-Fick Ian diffusion, so showing less diffusion in the 
media. In addition, the release rate constant (k) was higher for the sodium alginate than the 
hydroxypropylmethyl composite particles.  
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Table 4.6. Kinetics Parameters of Hydrogel Loaded with ovalbumin particles and captopril. 
Gel 
Formulae 
       Zero-order     First-order Higuchi-
model 
Korsemeyer-model 
 R2               K (% h -1)          R2           R2         R2            n 
HPMC 0.8387      2.541     0.8904     0.4657 0.6887          0.242 
PVA 0.8133      3.042     0.8193     0.7172 0.7939          0.277 
NaAlg 0.9415      4.529     0.9867     0.7800 0.9567          0.426 
r2 coefficient of determination. K rate constant according to zero-order analysis. n diffusional 
exponent Korsemeyer model indicative of the mechanism of drug release.  
a Analysed by the regression coefficient method. 
 
4.4. Concluding Remarks 
Various hydrogels were used, which influence to the drug entrapment efficiency, size 
distribution, mean particle size, surface morphology, swelling behaviour and in- vitro drug 
release. Sodium alginate, hydroxypropylmethyl cellulose and polyvinyl alcohol particles were 
prepared and from the data and analysis it was clear that sodium alginate provided the best 
combination of hydrogel properties of the three formulations. Sodium alginate particles 
resulted in the highest drug release of 78% as compared to hydroxypropylmethyl cellulose 
and polyvinyl alcohol particles which released 40% and 61% of captopril. The sodium 
alginate particles also provided the best drug entrapment efficiency, size distribution, mean 
particle size, surface morphology and swelling behaviour.  The combination of the ovalbumin 
polymer with that of sodium alginate has shown good interaction for the prolonged release of 
a thiol-containing captopril, by providing a pharmaceutical dosage form for sustained 
captopril release. 
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Chapter 5 
Limiting Factors Affecting the Release of Captopril form the Ovalbumin-Captopril 
Carrier System 
 
5.1. Introduction 
Solubility is one of the most important physicochemical properties studied during the 
pharmaceutical preformulation. For solid or powder dosage form development, accurate 
solubility data are required for the robustness of the finished product. Furthermore there is a 
need to assess that the adequate amount of drug is released from the drug delivery system 
for absorption in vivo. If presumably a solid dosage form has a low aqueous solubility it may 
be subject to dissolution rate-limited or solubility-limited absorption in the gastrointestinal 
within the residence time (Soares et al., 2004; Wong et al., 1981). The importance of 
solubility in biopharmaceutical system is its use by the Biopharmaceutical Classification 
System (BCS) described by Amidon. This system describes low solubility compounds as 
those whose solubility is less than that of the total dose tested in 250mL of 1-7.5 pH 
aqueous solution (Zhang et al., 2009). Solubility values are used to estimate the Maximum 
Absorbable Dose (MAD), which is influenced by many variables including temperature, pH, 
solvents used in the solubility test, the state of solid, polymer concentrations, common ions 
in the medium and so on (Guirguis et al., 2012).  
Within the field of controlled drug release and timed release systems, it is vital to understand 
the dissolution behaviour of polymers.  In most of these systems the bioactive is usually 
dispersed in the matrix of the polymer, and when introduced into a suitable solvent for the 
polymer, swelling usually results (Wang et al., 2011). The swelling allows the solvent to 
permeate the polymer matrix, resulting in increased mobility of the bioactive which allows the 
bioactive to diffuse out the matrix into the surrounding medium. Normally these systems 
produce programmable concentration-time profiles that produce optimum therapeutic 
responses (Millard et al., 2002; Luener et al., 2000). The design of the controlled drug 
delivery system provides stability both in vivo and in vitro for unstable bioactives, while also 
providing an increased residence time at the site of action. Bioactives that would otherwise 
be discarded for being unstable or have reduced bioavailability may now be rendered useful 
due to a selection of novel polymeric drug delivery system (Amidon et al., 1995; Wang et al., 
1999). 
In order to achieve a successful oral drug delivery system for gastric sensitive bioactives, 
there is a need to protect them from the harsh gastric environment. pH-sensitive hydrogels 
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are employed as alternative choices against the biodegradation of the bioactive in the lower 
pH (~1.2) found in the stomach. Swelling of these hydrogels should be minimal at lower pH 
thus reducing the amount of bioactive lost by the drug delivery system. At higher pH as 
those found in the intestine, swelling of the hydrogels should be increased gradually. 
Alginate is one such polymer that is known for its swelling abilities at higher pH.  Alginate is 
a water soluble linear polysaccharide extracted from brown seaweed and is composed of 
alternating blocks of 1-4 linked α-L-gluronic and β-D-mannuronic acid residues (Shargel et 
al., 1999; Xing et al., 2003). The crosslinking ability of alginate to ions such as Ca2+, Ba2+ or 
Sr+ retains the biological activity of the bioactive by encapsulating in the bioactive during the 
process of crosslinking. The covalent binding ability of the alginate polymer to thiol surfaces 
also makes it a novel choice in a hydrogel. Thiolated polymers such as alginate attach to 
mucoadhesive surfaces forming disulphide bonds with the mucus surface increasing contact 
between the hydrogel matrix and intestinal wall thus resulting in an increased retention time 
allowing increased drug absorption across the intestinal wall [Gum et al., 1992; Schnurch et 
al., 2001; Kuashlik et al., 2011). In addition to the improved adhesive properties, swelling 
behaviour and cohesive properties are also improved which makes alginate a useful 
excipient for the prolonged controlled drug delivery system (Karuppaiya et al., 2009). For the 
formulation of a prolonged release drug delivery system in the form of a capsule, specific 
polymer factors are required. Figure 5.1 demonstrates the simulated 3D conjugation process 
of sodium alginate and ovalbumin. 
 
Enteric coated capsules also directly contribute to the delay onset of action of the 
encapsulated excipients. To a certain extent, enteric coated formulations postpone onset of 
action via targeted release in the intestine (Bingol et al., 2010; Bingol, 2010;Das et al., 2011; 
Fakri et al., 2013). The active substance content in a core with an enteric coating can be 
released about two to three hours later than the initial dosage coated thereon. Delaying the 
onset of action achieved to improve the biological availability of medicaments. Targeted 
release in the small intestine may be used to achieve higher local active substance 
concentrations (Cojocaru et al., 2007). 
 
Enteric coatings are in particular used to: 
 
• protect active substances destroyed by the acidic gastric juice, 
• improve tolerability of medicaments irritating the stomach by only releasing them in the       
small intestine, 
• making active substances available after a time delay (sustained release), 
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• achieve targeted release and concentration in the small intestine (Thoma et al., 1992) .  
 
Hard gelatin capsules of provided they display adequate resistance and disintegration 
properties, are pharmacokinetically appropriate and meet stability requirements.  Coatings 
on capsules this type display important potential applications in: (1) ensuring biological 
availability, (2) controlling the effects of medicaments and, (3) avoiding side effects (El-
Malah et al., 2006; Shargel et al., 1999; Arai et al., 2009).  
 
The aim of this chapter was to analyse the responses of the components that make up the 
ovalbumin drug carrier system for optimization in the chapter to follow. The aim was to 
further determine the parameters of each excipient and the effect each component has on 
the performance of the ovalbumin captopril carrier system.  
            
 
Fig.5.1. Simulated 3D conjugation of sodium alginate and ovalbumin using Hyperchem 
software. 
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5.2. Analysis of the thermal effects on the sodium alginate nanoparticles 
5.2.1. Materials and Methods 
5.2.2. Materials 
Purified lyophilised ovalbumin (OVA), Dithiothreitol (DTT), and captopril were purchased 
from Sigma (Sigma Aldrich, Missouri, USA). Ethanol, Sodium Alginate, Potassium 
phosphate monobasic and Disodium hydrogen phosphate were purchased from Merck 
(Merck KGaA, Darmstadt, Germany). All the chemical agents were analytic grade and used 
without further purification. It should be noted that no differences were found between the 
Sigma obtained ovalbumin and the self purified native ovalbumin.  
 
5.2.3. Methods 
5.2.3.1. Effects of the pH and salt concentrations of the ovalbumin native polymer  
Native ovalbumin solutions were prepared by Differential Scanning Calorimetry (DSC) was 
performed on the DSC (1 STARe system, Mettler Toledo, Schwerzenbenbach, Switzerland).  
Two sets of chemically treated ovalbumin solutions were prepared. Firstly 20mg of 
ovalbumin solutions were prepared and treated with 0, 0.5 and 1.0M of sodium chloride 
solutions. Secondly, a separate 20mg of native ovalbumin were dissolved in pH buffer 
solutions of 1.2, 4.0, 6.8 and 10 and both were heated from 25 to 100°C at 1 °C/min, 
individually. The samples were placed in silver sealed containers (70µL) and weighed on 
average 30mg. The denaturation temperature (Td) was evaluated using STARe software. 
The total enthalpy change and the enthalpy changes of the individual components were 
determined by integration of the peak area upon deconvolution of the recorded thermogram. 
 
5.2.3.2. Limiting factors affecting captopril release from the ovalbumin carrier system                                                             
5.2.3.2.1. Preparation of the sodium alginate ovalbumin captopril particles 
The ovalbumin-captopril conjugate were encapsulated with sodium alginate (NaAlg) using 
calcium chloride. Preparation for the nanoparticles was as follows: Sets of hydrogel coatings 
were prepared using cation-induced controlled gelification methods. In the various polymeric 
solutions 5mL of CaCl2 with varying concentrations were added dropwise to 50mL of the 
above sodium alginate polymer solutions while stirring. Ovalbumin-captopril solution (20mL) 
was injected into the hydrogel solution dropwise using a 10mL syringe while stirring. The 
resultant biopolymeric solution was then agitated overnight on a magnetic stirrer (CNW 21-2 
Homothermal, China) at room temperature. The polymeric solution was then pre-freezed at -
70°C for 24 hour and lyophilized at 1.35mmtorr for 24 hour. The combinations of the 
variables used are tabulated below, Table 5.1.  
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Table 5.1. Limit determinations of the upper and lower variables. 
Variables Lower  Upper 
Ovalbumin 100mg 250mg 
Sodium alginate 0.04 (w/v %) 0.08 (
v/v %) 
CaCl2 12mM 24mM 
 
5.2.3.2.2. Drug Release Analysis 
The in vitro release experiments were performed in simulated intestinal fluid (SIF) pH 6.8 in 
USP Apparatus 2. Each set of the nanoparticles, equivalent to 100mg of captopril, were 
accurately weighed and placed in 500mL glass volumetric flasks containing 500mL of the 
simulated intestinal fluid at 37°C. Samples (1mL) were taken from the release medium at 
specific time intervals for a total of 24hour and replaced by fresh 1ml SIF buffer solution. pH 
1.2 and 7.4 drug release profiles were also assessed to measure the different gastric and 
intestinal drug release percentages. Sink conditions were maintained by replacing the 
withdrawn 1mL samples with simulated intestinal fluid at each sampling time. The 
concentration of the drug released was determined utilizing the Ultraviolet 
Spectrophotometer (Cecil CE 3021, 3000 Series, Cecil Instruments, Cambridge, England) at 
λ271nm. From this concentration value the actual amount of drug was then calculated. 
 
5.3. Results and Discussion 
5.3.1. Results 
5.3.1.1. Effects of pH and salt on the denaturation of the ovalbumin protein 
Thermal characterisation of food and pharmaceutical consumables is important especially if 
the contents thereof contain proteins (Behnken et al., 1999). It is well known that the thermal 
characterisations of proteins are affected by pH, temperature, ion intensity and protein 
concentration. By treating natural polymers such as ovalbumin with salts, sugars, acidity and 
alkaline chemicals, the resultant effect is a shift or change in the stability of the protein 
(Govender et al., 2005). These conformational changes vary in the effect they have on the 
structure of the protein. At isoelectric point, the protein is uncharged and charge repulsions 
of similar functional groups are generally minimal, which allows for aggregation to take 
place. Many proteins precipitate under these conditions, and even for proteins that remain in 
solution at their isoelectric point this is the pH of minimum solubility (Ferriera et al., 2007). 
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Figure 5.2 demonstrated the effect cationic or anionic ovalbumin would display when placed 
in an acidic or alkaline pH, and its effect on drug release. The shrunken state would 
ultimately decrease the total amount of captopril released and the swollen state would be 
vice versa. In Figure 5.2 the thermal effect of different pHs on ovalbumin was assessed at 
pH 1.6, 4.0, 6.8 and 10 using DSC. It showed that as the pH increased, the denaturation 
curve increased, resulting in a shift to lower temperatures of 60°C. Contrastingly in Figure 
5.3, as the CaCl2 concentration was increased there was a decrease in the denaturation of 
ovalbumin and a shift to higher temperatures of 80°C. Consequently, a significant captopril 
increment would be noticed (Rothgang et al., 1975). Schematic 5.2 showed that the increase 
in ionic strength of CaCl2 could have caused instability, reduced polymer solubility, and 
polymer precipitation which results in reduced viscosity. It also showed that changing pH to 
higher values increases the stability of proteins and the heat effect of unfolding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2. The response of cationic or anionic ovalbumin to pH values of acidity and 
alkalinity. Adapted from Mastropietro et al.,(2013). 
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Fig.5.2. The DSC curves for the analysis of comparing the thermal effect of different pHs on 
the ovalbumin. 
 
 
 
 
 
 
  
         
 
 
Fig.5.3.The effect of ions on the ovalbumin polymer solubility and viscosity. Adapted from 
Mastropietro et al.,2013. 
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Fig.5.3. DSC curves comparing the thermal effect of different CaCl2 salt concentrations on 
ovalbumin.  
 
5.4.2. Drug Release Analysis 
Figure 5.4 showed very little if no significant difference in the fractional release of captopril. 
This could be due to the dissolution of the disulphide bond formed between the ovalbumin 
polymer and captopril being broken due to the abundant hydrogen molecules found in the 
7.2 medium. The drug entrapment was measured on average at 79.1±6.5%. 
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Fig.5.4. Comparison of the effect of different masses the ovalbumin polymer has on the 
release of captopril.  
 
The effect of different concentrations of hydrogel in this case sodium alginate, showed 
similarity in the shape of the drug release profile. Both drug release profiles demonstrated 
first-order drug release profile, with the only difference being the fractional percentage of 
drug released with 0.08 w/v sodium alginate at 98% and 0.04 w/v at 88%, (Figure 5.5). This 
could be because of the increased availability of hydrogen moieties on the more 
concentrated sodium alginate than the less concentrated, but as mentioned previously the 
total fractional release was generally similar with little statistical difference. p-Value of 
<0.005. 
The effect of the concentration of CaCl2 on the release rate of captopril showed no significant 
difference between the chosen lower and upper level concentrations. This signifies the 
important role CaCl2 played in the crosslinking of the hydrogel to the ovalbumin polymer, but 
the concentration did however affect the drug release profile obtained. From Figure 5.6 it 
was evident that the lower concentration of 12w/v CaCl2 displayed a first-order drug release 
profile with a 1hour burst effect while the higher concentration displayed a zero order drug 
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release profile. The lower concentrations of CaCl2 showed an initial drug burst release effect, 
which could be due to rapid swelling of the hydrogel. This type of drug release would be 
suited for an immediate response drug delivery system, with prolonged drug effects 
maintained in the blood stream.  
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Fig.5.5. Comparative drug release profile of showing the effect of sodium alginate (NaAlg) 
variable. 
 
At a lower pH the release rate and total amount of the drug released was reduced, because 
of the reduction in the swelling ability of sodium alginate at pH 1.2 (Figure 5.7). The rate of 
diffusion into the hydrogel was reduced due to the decreased ionic interaction between the 
hydrogel and water molecules.     
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Fig. 5.6. Comparative drug release profile of the effect of calcium chloride (CaCl2) on the 
release of captopril.  
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Fig.5.7. Comparative drug release profile of the different effects pH has on the release of the 
captopril.  
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5.4. Concluding Remarks 
The importance of drug release in pharmaceutical preparations is very important. If a drug is 
not getting dissolved or miscible in vehicle then it becomes very difficult to administer it and 
hence forth it shows poor bioavailability. The release of captopril from the ovalbumin carrier 
system was determined by many factors, including the amount of the polymer excipients, the 
polymer interactions with other excipients such as the calcium chloride cross-linker and the 
concentrations of the hydrogel. The functionality of the ovalbumin vehicle system was 
dependent on the quantities of the individual excipients, their concentrations and the optimal 
pH at which the release of the drug was optimal. The drug release from the particles was 
affected by the pH of the dissolution medium results more sustained effect in alkaline 
medium. The release of the captopril from the ovalbumin carrier system was also dependent 
on the pH, calcium chloride effects on the native ovalbumin itself. It can be concluded that 
the selected excipients have enhanced the release of captopril from the ovalbumin vehicle 
system. 
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CHAPTER 6 
Optimisation of the ovalbumin drug carrier system 
 
6.1. Introduction 
Drug delivery systems require a detailed understanding of the relationship between process 
parameters and quality attributes. It is necessary to develop a science based design system 
to identify multidimensional combinations of the many casual factors that determine target 
quality (Gohel et al., 1971). It is however difficult to obtain an optimised formulation with 
rapid and complete dissolution using the old formulation screening and optimisation process, 
one-factor-at-a-time. The single factor optimisation process does not consider the 
interactions between factors and may require a large number of experiments (Nazzal et al., 
1981).  
Various experimental designs have been designed to reduce the experimentation process 
and provide estimates of the relative significance of different variables of a formulation 
(Chang et al., 2007; Yasir et al., 2013; Hao et al., 2011). In recent years, the application of 
statistical experimental designs to formulations have shown a high level of success in 
understanding the relationship between independent and dependent variables in a 
formulation. The response surface methodology (RSM) was useful in the simultaneous 
analysis of variables and their interactions when the interactions are complicated. The 
success in many studies demonstrated the value of response surface methodology for 
obtaining optimal formulation in various drug delivery systems (Gazori et al., 2009; Fakri et 
al., 2013).    
RSM is a statistical technique that uses quantitative data obtained from appropriately 
designed experiments to determine regression model and operating conditions (Jabasigngh 
et al., 2010). It was developed to build mathematical models which allow one to assess the 
effects of several factors onto a desired response. It is suitable for multi-factor experiments 
and investigates the common relationship between various factors for the most favourable 
conditions of the processes (Laurent et al., 2008). 
The Box-Behnken design is an independent, rotatable quadratic design, i.e. contains no 
embedded factorial or fractional factorial design, in which the treatment combinations are at 
the midpoints of the edges of the process space and at the centre (Nguyen et al., 2008; Biro 
et al., 2009). Experimental designs have been used frequently for nanoparticle optimisation 
considering the advantages such as, (1) reduction in the number of experiments that need to 
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be performed, (2) development of mathematical models to assess the relevance and (3) 
statistical significance of the factor effects, and evaluation of interaction effect between 
studied factors (Jarrott et al., 1981; Medvedovici et al., 2009; El-Kamel et al., 2006; Hayashi 
et al., 1985). Box-Behnken designs are based on a 3-level incomplete factorial design and 
are useful tools for optimisation following response surface methodology because it permits 
estimation of the parameters of the quadratic model, building of sequential designs and 
detection of lack of model fit (Darren et al., 2009). A Box-Behnken design does not contain 
combinations for which all factors are simultaneously at highest and lowest levels, avoiding 
experiments performed under extreme conditions for which unsatisfactory results might 
occur (Woitiski et al., 2010). The purpose of this study was to optimize nanoparticle 
formulation for orally dosed captopril, investigating the relationship between design factors 
and experimental responses via a response surface methodology specifically a with Box–
Behnken experimental design. 
 
6.2. Materials and Methods 
6.2.1. Materials 
Purified lyophilised ovalbumin (OVA), Dithiothreitol (DTT), and captopril were purchased 
from Sigma (Sigma Aldrich, Missouri, USA). Ethanol, Sodium Alginate, Potassium 
phosphate monobasic and Disodium hydrogen phosphate were purchased from Merck 
(Merck KGaA, Darmstadt, Germany). All the chemical agents were analytic grade and used 
without further purification. It should be noted that no differences were found between the 
Sigma obtained ovalbumin and the self purified native ovalbumin.  
 
6.2.2. Methods 
6.2.2.1. Preparation of the ovalbumin drug delivery hydrogel matrices in accordance 
with the Box-Behnken experimental design template 
Fifteen formulations were prepared using various combinations of the processes of 
interphase, co-particulate, co-solvent, pre-freezing and lyophilisation guided through a two-
level, three factor and three centre points Box-Behnken quadratic design using Minitab 
Statistical Software, Version 14 (Minitab Inc., State College, PA, USA). Three categories of 
independent variables composed of the two primary polymer concentrations and the linker 
were employed in formulating the ovalbumin drug delivery systems. As previously stated the 
analysis was based on a statistically and mathematically generated Box-Behnken design 
template.  
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Each compound employed in formulation of the fifteen formulations and their rationales for 
their selections are outlined in Table 6.1. Combinations of both the polymeric and non-
polymeric additives were employed in the fabrication of the drug delivery systems in order to 
facilitate the development of an effective formulation with the optimum physicochemical and 
performance performance qualities suitable for the intended application as an oral drug 
delivery system.  
 
Table 6.1 and 6.2 present the variables selected, the two levels of the independent variables 
employed and the experimental design template for the 3 factors, 3 centre points and the 15 
experimental runs respectively. The lower and upper limits for the factors were set based on 
their ability to form stable, sustained release drug loaded systems, using minimal quantities 
of the individual components. 
 
Table 6.1. Rationale for the selection of the variables employed in the experimental design. 
Component                 Rational for selection and Function 
Ovalbumin                    Thiol conjugate, drug carrier/vehicle 
Sodium Alginate           Permeation enhancer, control release polymer properties 
Calcium Chloride          Polymer cross-linker 
 
Table 6.2. Levels of independent variables employed in the Box-Behnken design template. 
Independant Variable                               Levels                                      Units 
                                                 Low                            High 
Ovalbumina                              100                              250                            mg 
Sodium Alginateb                      0.04                            0.08                           mM 
Calcium Chloridec                      12                               24                             mM 
a Ovalbumin, b Sodium Alginate, c Calcium Chloride. 
 
 
 
 
 
 
 
94 
 
Table 6.3. Box-Behnken Template for the preparation of each of the 15 formulations. 
Formulation                                                Composition 
                                NaAlg (mg/ml)           Ovalbumin (mg)                 CaCl2 (mg/ml) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10* 
11 
12 
13* 
14* 
15 
0.08 
0.04 
0.04 
0.04 
0.06 
0.04 
0.06 
0.06 
0.08 
0.06 
0.06 
0.08 
0.06 
0.06 
0.08 
100 
100 
250 
175 
100 
175 
100 
250 
250 
175 
250 
175 
175 
175 
175 
18 
18 
18 
12 
24 
24 
12 
24 
18 
18 
12 
12 
18 
18 
24 
 
*Centre points of the Box-Behnken Design template 
 
Fifteen ovalbumin captopril carrier formulations were prepared using predetermined 
quantities of ovalbumin, sodium alginate and CaCl2 according to Table 6.3. The 
combinations of the polymeric and non-polymeric solutes, ovalbumin and sodium alginate 
were dispersed separately in deionised water and ethanol respectively.  
Briefly, each formulation contained 50mg of captopril which was dispersed in the aqueous 
sodium alginate. The two dispersions (ovalbumin and sodium alginate) were homogenised 
together and the respective quantities of were used to increase the crosslinking of both the 
polymeric dispersions. The crosslinking process was used to enhance homogenization to 
form stable particles with a single continuous phase. The resulting blends of the 15 
ovalbumin captopril carrier formulations formulations were pre-frozen at -72°C for 24 hours 
to aid the formulation of the homogenous blend and then subjected to lyophilization by 
placing them into a freeze dryer (Bench Top 2K, Virtis, New York, USA) set at -48 ± 5°C, at a 
pressure of 0.42mBar for 24 hours.  
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Post lyophilisation produced white powdered batches of the 15 formulations and the samples 
were stored at room temperature (25 ± 5°C) until further use. To prevent atmospheric water 
absorption by the individual formulations, active silica-containing desiccant bags were 
packaged with the formulations. 
To determine the actual amount of captopril loaded, each of the fifteen formulations were 
individually dissolved in 100mL of simulated intestinal fluid (pH 6.8). The release medium 
(2mL) was manually withdrawn after 24 hours and filtered through with a 0.22µm pore sized 
filter (Millipore Corporation, Bedford, MA, USA). The sample was diluted accordially and the 
absorbance was measured to determine the concentration of the captopril released, utilizing 
the Ultraviolet Spectrophotometer (Cecil CE 3021, 3000 Series, Cecil Instruments, 
Cambridge, England) at λ271nm. From this concentration value the actual amount of drug 
was then calculated. All experiments were carried out in triplicate. 
 
6.2.2.2. Evaluating the in vitro drug release behaviour of the sodium alginate 
ovalbumin optimisation formulae 
Drug release studies were conducted by immersing each of the previously mentioned 15 
formulations into 500mL of simulated intestinal fluid pH 6.8. The experiments were 
performed in similar conditions as mentioned above, and three replicate samples of each 
individual formulation were analyzised. For experimental compliance, the temperature was 
maintained at 37°C ± 0.5°C and 90 rpm using the USP II dissolution system (Erweka DT 
700, Erweka GmbH, and Huesenstamm, Germany). 1mL dissolution samples were manually 
withdrawn at the following predetermined time intervals 30 minutes, 1, 2, 4, 6, 8, 10, 12, 16, 
20, 24 hours and filtered thorough a 0.22µm pore sized filter (Millipore Corporation, Bedford, 
MA, USA). Sink conditions were maintained by replacing the withdrawn 1mL samples with 
freshly prepared simulated intestinal fluid at each sampling time. The concentration of 
captopril released was determined utilizing the Ultraviolet Spectrophotometer (Cecil CE 
3021, 3000 Series, Cecil Instruments, Cambridge, England) at λ271nm. From this 
concentration value the actual amount of drug was then calculated. 
The varied dissulotion patterns were analysed and substantiated by the time-point approach 
reffered to as the mean dissolution time (MDT). The mean dissolution time provides an 
accurate view of the drug release behaviour as it was determined as a sum of the individual 
periods of which a specific fraction of the total drug was released. 
 
MDT= ∫
(M-M(t))
M
dt
∞
0
                                                                                                     (6.1) 
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Where Mt is the fraction of dose released at time ti. ti= ti+ti-1/2 and M∞ corresponds to the 
loading dose. 
 
6.3. Results and Dicussion 
6.3.1. Cumulative drug release profiles of the Box-Behnken experimental design 
formulations  
All the 15 ovalbumin captopril carrier formulations elicited variable levels of captopril release 
for the 24 hours time period. The drug carrier system demonstrated the potential for 
application as a controlled release system over the 24 hour period. The levels of both natural 
polymers to cross-linker contained in each formulation appeared to have noticeable effects 
on the drug release pattern. A summary of the responses of each the ovalbumin captopril 
carrier formulations were tabulated in Table 6.4. 
Generally, the ovalbumin captopril carrier formulations comprised of higher levels of 
ovalbumin displayed a more controlled release pattern while the reverse was observed for 
those containing higher levels of the hydrogel, sodium alginate. Figure 6.1 (a-d) 
demonstrated the observed trend of captopril release may be advantageous to the intended 
application of the drug delivery system as a controlled prolong release drug delivery system. 
Overall, the differences in the quantities of the formulation constituents could have 
influenced the water influx and hydration, particle size which influenced the captopril release 
behaviour of each formulation. Based on the limiting response variables tabulated in Table 
6.4, the responses targets were determined by the Box-Behnken design. Table 6.5 
summarises the response results for the 15 ovalbumin captopril carrier formulations, which 
include the size and zeta-potentials of the particles, the mean dissolution time and 
cumulative captopril release of 24 hours.  
 
Table 6.4. Targets for the selected response parameters. 
Responses  Lower Target Upper  
Zeta-potential (mV)   -27.7 -27.7 -29.4 Maximize 
Mean dissolution time        0.0149       7.0      7.056    Minimize 
Drug entrapment efficiency(%)        38.88       45.1      45.1    Maximize 
Accumulated drug Release  55.2  96  98.6  Minimize 
Size (nm)        99.78       220      283.9    Minimize 
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Fig. 6.1.a. Drug release profiles for F 1-4. b. Drug release profiles for F 5-8. c. Drug release 
profiles for F 9-12. d. Drug release profiles for F 13-15. Average SD±0.67. 
d. 
c. 
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Table 6.5. Cumulative Results of the independent variables of the Box-Behnken 
Experimental Template. 
Formulation Size 
(nm) 
Z-pot. 
(mV) 
Cum. 
Release   
(%) 
 MDT 
(hr) 
DEE 
(%) 
1 166.8 -24.4 70.65 6.920 39.17 
2 99.78 -26.2 89.30 3.772 38.88 
3 110.4 -29.4 55.20 6.551 40.11 
4 226.8 -23.6 78.60 6.076 40.73 
5 283.9 -25.4 76.90 3.603 39.46 
6 240.0 -25.4 73.50 4.476 44.39 
7 201.2 -22.3 79.20 0.015 40.03 
8 255.6 -22.4 40.83 4.471 42.76 
9 142.1 -26.1 85.34 2.758 44.60 
10 138.7 -26.5 76.78 7.456 44.96 
11 166.5 -20.4 78.98 4.885 43.40 
12 121.5 -23.0 77.28 3.679 45.50 
13 138.8 -26.7 76.83 7.322 44.14 
14 138.7 -26.8 76.77 7.475 44.55 
15 201.4 -20.7 87.03 0.999 46.50 
 
 
6.3.2. Elucidation of the variable responses using the Box-Behnken Design Template 
6.3.2.1. Surface Plots  
The surface plots of the response functions are useful in understanding both the main and 
interaction effects of the factors (Arai et al., 2009). The 3D surface plots of the response (Y) 
indicated the same results as observed in the interaction plot.The surface plots for size and 
zeta-potential are indicated in Figure 6.2. i and ii. The surface plot of size versus calcium 
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chloride and ovalbumin (Figure 6.5.a) indicate that size was highest when ovalbumin and 
calcium chloride were 250mg and 25mM respectively.  The zeta-potential was highest when 
calcium chloride was 25mM and the sodium alginate was 0.06w/v, Figure 6.2.ii. The zeta-
potential increased with increased calcium chloride concentrations, whereas the size of the 
particle increased with increased ovalbumin and sodium alginate concentrations. The 
concentration of calcium chloride also increases zeta potential to values lower than -20 mV, 
affecting the stability of nanoparticles in suspension.  
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Fig. 6.2.i. 3-D Response surface showing the influence of the concentration of calcium 
chloride and ovalbumin on the average particle size of the nanoparticles. ii. surface showing 
the influence of the concentration of calcium chloride and ovalbumin on the average zeta-
potential of the nanoparticles. iii. surface showing the influence of the concentrations of 
sodium alginate and ovalbumin on the percentage drug entrapment efficiency of the 
nanoparticles. iv. surface showing the influence of the concentration of sodium alginate and 
ovalbumin on the cumulative drug release. 
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6.3.2.2. Comparative of the Box-Behnken formulations for size and zeta-potential 
All formulations yielded a zeta potential below -20mV, which was indicative of good stability 
of the particles. The size of the particles varied with Formulation 2 yielding the smallest 
particles, 99nm and Formulation 5 the largest particle sizes, 283.9nm. Particles with small 
size are highly desirable in order to increase contact with the intestinal mucosa due to higher 
surface area per volume and mucoadhesive strength (Darren et al., 2009) also increasing 
nanoparticle uptake through the intestinal mucosa. Figure 6.3 showed a summary of the size 
and zeta-potential 15 ovalbumin captopril carrier formulations  
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Fig.6.3. Summary of the size and zetapotential for the 15 Box-Behnken Design formulations. 
 
6.3.2.3. Response surface analysis of the mean dissolution time and drug entrapment 
efficiency 
Response surface analyses were plotted in three-dimensional model graphs for optimization 
of nanoparticles with physicochemical properties for the ovalbumin drug carrier system. The 
three-dimensional response surface plots for drug entrapment efficiency and accumulated 
drug release percentage were analysed. Entrapment efficiency is influenced by ovalbumin 
concentration as seen in Figure 6.2.iii., when calcium chloride was kept constant. In Figure 
6.4 a summary of the comparison across all the 15 formulations was shown.  
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Fig.6.4. Summary of the the drug entrapment efficiency for the 15 Box-Behnken Design 
formulations. 
It can be concluded that from Figure 6.5. (i and ii) the mean dissolution time was directly 
increased by ovalbumin, sodium alginate and calcium chloride.  
Fig.6.5.i. Contour plot showing the influence of the concentration of sodium alginate and 
calcium chloride on the mean dissolution time. ii. Contour plot showing the influence of the 
concentration of ovalbumin and calcium chloride on the cumulative drug release percentage. 
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A summary of the mean dissolution time and accumulated release of the ovalbumin captopril 
carrier formulations were provided in Figure 6.6. It should be noted that the higher the 
concentration of ovalbumin the lower the MDT. 
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Fig.6.6. Summary of the the drug mean dissolution time and cumulative drug release for the 
15 Box-Behnken Design formulations. 
 
6.3.2.4. Residual Plots of the optimised ovalbumin-captopril formulations  
Residuals plots may be employed to analyze the fit of regression models in a Box-Behnken 
Design. These plots can be defined as measuring the variation between the actual observed 
responses and the predicted responses. On analysis of k and the R2 values for the drug 
release from the predetermined variables, it was found that there was an indiscriminate 
distribution of data. The scatter of data observed in the residual versus fitted value plots 
showed a random arrangement of data indicating that the fit of the data linear regression 
model was of a satisfactory nature. The residual histogram exhibited nearly bell-shaped 
curves with the exception of a few, namely the cumulative drug release and the drug 
entrapment efficiency. The bell-shaped histogram curves were indicative of normal data 
distribution. The non bell-shaped histograms as mentioned previously were indicative of an 
aspect of the data that was not accounted for in the model which suggested that the error 
terms did not correlate amongst one another. The observed residual were linear for the 
entrapment efficiency, mean dissolution time and accumulated drug release (Figure 6.7. a-
c). 
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Fig.6.7.a. Residual plot for the drug entrapment. b for the mean dissolution time, and c. for 
the cumulative drug release.   
 
6.4. Response Optimised  
6.4.1. Fabrication of the optimised formulation 
The optimised formulation was obtained from Minitab®, V14 (Minitab® Inc, Pennsylvania, 
USA). The optimised formulation was in accordance with the independant variables and the 
responses obtained.  
6.4.2. Application of the desirability functions for size and zeta-potential 
The desirability function was employed to obtain an optimal formulation of the four 
responses from the chosen independant variables. The responses were transformed to 
achieve a desirability target of 1. The responses were set into a lower, middle and upper 
response values for the independant values ovalbumin, calcium chloride and sodium 
alginate. The optimal formulation comprised of low levels of ovalbumin and sodium alginate 
were minimised and high levels calcium chloride. Figure 6.8 illustrated the set desirability 
functions in red and the responses in blue of the size and zeta-potential of the ovalbumin 
captopril carrier formulations. 
                           
c 
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Fig.6.8. Optimised plots and desirability functions for the size and zeta-potential of the drug 
carrier system. 
                                
Fig.6.9. Desirability functions for the drug entrapment and mean dissolution time of the drug 
carrier system. 
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For the desirability function, calcium chloride was minimised, sodium alginate and ovalbumin 
were maximised, (Figure 6.9) in red. The responses in blue for the captopril entrapment and 
mean dissolution time of the ovalbumin captopril carrier formulations were calculated as 
y=1.99 and y=45.34 for mean dissolution time and drug entrapment efficiency respectively. 
 
Table 6.6. Levels for the fabrication of the optimised drug delivery system. 
Composition                                                             Optimised Level 
Ovalbumina                                                                  250 mg 
NaAlgb                                                                         0.080 mg/mL 
CaCl2
c                                                                          12 mg/mL 
 a Ovalbumin – ethanol based co-particulate dispersion. 
b Sodium Alginate – aqua based dispersion. 
c Calcium Chloride - crosslinker 
 
Based on the optimization results, a formulation was developed for the synthesis of the 
optimized formulation (Table 6.6). The synthesised optimized formulation was assessed to 
ascertain the existence of a correlation between the experimentally and fitted data as well as 
confirming the suitability of the experimental design employed. The formulation was 
assessed based on its drug entrapment, particle size, zeta-potential, accumulated drug 
release and mean dissolution time. The drug release was designed as a 24 hour prolonged 
release system to aid patient compliance. 
 
The optimised formulation had a drug entrapment efficiency mass of 44.5mg, a drug release 
percentage of 89% and an average mean dissolution time of 2.05 hours. The average sizes 
of the particles were 200nm and the zeta-potential was slightly higher than the predicted at   
-25mV. The optimized ovalbumin drug release carrier system retained its structure, of 
spherical particles. The representative drug release profile for the optimised formulation is 
shown in Figure 6.10. The optimised formulation displayed consistency in its drug release to 
those reported in the experimental design. The drug release of captopril was stable over the 
24 hour period. 
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Fig.6.10. The drug release profile of the optimised ovalbumin drug delivery carrier system. 
 
5.5. Concluding Remarks 
The experimental design allowed the systematic optimization of the ovalbumin drug carrier 
system formulation to be examined. The optimization process determined the 
physicochemical parameters important for the oral dose of captopril, evaluating the most 
important factors and their observed responses. It investigated the relationship between 
factors affecting the performance of the ovalbumin drug carrier system using the response 
surface methodology. Box–Behnken design was successfully used to statistically optimize 
the formulation parameters and to evaluate the main interaction and quadratic effects of the 
independent variables on the particle size, zeta potential, entrapment efficiency and captopril 
release in simulated digestive fluids. A 3-factor, 3-level design was used to explore the 
quadratic and linear response surfaces and for constructing a zero order polynomial model.  
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CHAPTER 7 
In vivo Investigation and Analysis of the Optimised Ovalbumin Prolonged Drug 
Delivery System. 
 
7.1. Introduction  
Captopril as previously stated, is a known antihypertensive, which works by inhibiting the 
angiotensin-converting enzyme (ACE). It has proven to be an effective and an outstanding 
clinical treatment for hypertension and congenital heart failure (Kripalani et al., 1980; Uslu et 
al., 2013). In most cases it is widely used as a first choice of drug for the treatment of 
hypertension. Despite its effectiveness as a an antihypertensive, captopril can at most 
regulate hypertension for a period of up to 8hour, which would require the a daily dose of 37-
75 mg clinically thourice a day (Earl et al., 1964). It has a known short half-life of about 2hour 
and is metabolised to a n-carboxyl derivative in the liver and excreted mainly unchanged in 
the urine (Kok et al., 1997; Tache et al., 2002).  It has been reported that captopril has a 
bioavailability of 70-75% (Rezende et al., 2007).  
 Hydrochlorothiazide is a thiazide diuretic, which acts moderately as a potent diuretic by 
reducing the reabsorption of electrolytes from the renal tubules in the kidneys (; Klein et al., 
1990; Pereira et al., 1988). Hydrochlorothiazide is generally well absorbed in the 
gastrointestinal tract and has a half-life of 5-15 h (Salem et al., 2005). It has a bioavailability 
of 65-75% and excreted unchanged mainly in urine (Lees et al., 1989; Foroutan et al., 2003). 
Both captopril and hydrochlorothiazide are used in treatment of hypertension either 
individually or in combination with other antihypertensives such as ACE inhibitors and beta 
blockers. They are specifically used to treat peripheral oedema associated with heart failure 
and renal as well as hepatic disorders. The combination of these drugs, captopril and 
hydrothiazide, are there indicated for the treatment and management of hypertension. Figure 
7.1. showed the structure of both captopril and hydrothiazide.  
Based on the halflife duration of both drugs in vivo, there was a necessity to develop a 
controlled captopril release delivery system that would ultimately maintain relatively constant 
blood levels of captopril for a longer period of time in vivo. Scheme 7.1. demostrated the oral 
administration of the ovalbumin drug carrier system. 
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Fig 7.1. Oral administration and absorption of the ovalbumin drug carrier system in a 
capsule also showing the absorption of the ovalbumin vehicle carriers.   
 
                   
(I)                                                                (II) 
Schematic 7.1. The structural formulae of captopril (I) and the internal standard 
hydrochlorothiazide (II), with circled reactive groups. 
 
Due to the thiol reactive nature of captopril, it tends to form disulphide bonds easily with 
endogenous thiol-containing compounds/proteins. The easily accessible thiol groups tend to 
form random disulphide bonds with other thiol containing compounds, pose a 
pharmaceutical challenge due to the reactive nature of the thiols. Therefore the 
determination of free or unchanged captopril concentrations have to be preceded by the 
addition of a chemical stabilizer in order to prevent captopril disulphide formation.  
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Several methods of determining the free or total captopril in human plasma have been 
reported. LC- based methods have been employed for the determination of captopril (Kamel 
et al., 2008; Synniewski et al., 1997). In most cases liquid-liquid or solid-phase extraction is 
necessary in order to concentrate or to perform sample clean-ups in both cases. LC/MS has 
been used widely as a main tool in the identification, characterization and quantitative 
analysis of drugs and their metabolites because of its superior sensitivity, specificity and 
efficient technique (Bald et al., 1997).       
There are unique advantages for the use of swines in this setting was that they share 
humans’ similar anatomic and physiologic characteristics involving the cardiovascular, 
urinary, integumentary, and digestive systems. The similarity of diseases between humans 
and pigs, such as e.g. arteriosclerosis, metabolic syndrome, gastric ulcer, and wound 
healing (Synpniewski et al., 1996) make the pig model a suitable alternative. Therefore, pigs 
are commonly used in research as preffered models for identification of new 
cardiovalbuminscular agents (especially in the field of arteriosclerosis and myocardial 
infarction), agents for treatment of metabolic syndrome (such as diabetes), dermatology 
drugs, and diagnostic agents. However, the researchers need to be familiar with important 
anatomic, histopathologic, and clinicopathologic features of the laboratory pig and minipig in 
order to put background lesions or xenobiotically induced toxicologic changes in their proper 
perspective and also needs to consider specific anatomic differences (Cavrini et al., 1996). 
In 1959, the report by Russell and Burch was published as 'The Principles of Humane 
Experimental Techniques', the basic tenet of their report being that “the humanest possible 
treatment of experimental animals, far from being an obstacle, is actually a prerequisite for a 
successful animal experiment.” 
The authors proposed the principles of Replacement, Reduction and Refinement (most often 
referred to as the 3R’s) as the key strategies to provide a systematic framework to achieve 
the goal of humane experimental techniques. In addition animal experimentations had 
principles that were meant to be followed by the researcher which are integrity, respect for 
persons or animals beneficence, and justice. 
The aim of the chapter was to assess the drug release of captopril from the ovalbumin drug 
carrier system in vivo. The objective was also to characterise and compare the release of 
captopril from the ovalbumin captopril carrier system in vitro and in vivo and ascertain the 
effectiveness of the delivery system.   
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7.2. Materials and Methods 
7.2.1. Materials 
Acetonitrile and formic acid were purchased from Aldrich® (Sigma–Aldrich Inc., St. Louis, 
USA). Other materials and excipients employed were of analytical grade and were utilized as 
purchased. Mobile phase used was acetonitrile (Merck, Wadeville, Gauteng, South Africa), 
orthophosphoric acid (Merck, Wadeville, Gauteng, South Africa) and double deionised water 
obtained from the Milli-Q System. The drugs used were captopril and hydrochlorothiazide 
(Sigma Aldrich, Steinhelm, Germany. Blood samples were analyzed with the Ultra 
Performance Liquid Chromatography model Waters Acquity Ultra Performance Liquid 
Chromatography System (Waters, Milford, MA, USA). The column used in the UPLC was a 
C18 column (2.1-50mm, 1.7μm particle size, Waters).  
 
7.2.2. In vivo ethics clearance 
The animal ethics clearance number for the research project was (2011/33/03) granted by 
the University of the Witwatersrand, Animal Ethic Committee (AEC), Johannesburg South 
Africa. 
 
Table 7.1. The amount of drugs to be used for the animal study. 
Drug/Substance Route Dose  Frequency 
Captopril Oral 50mg Administration of 
the drug will be 
done during testing 
Hydrochlorothiazide Oral 50mg Administration of 
the drug will be 
done during testing 
Ketamine Intramuscular 
injection 
100mg/kg Administered before 
Oral dosing and prior 
to euthanasia. 
 
Xylazine Intramuscular 
injection 
5mg/kg Administered before 
Oral dosing and prior 
to euthanasia. 
 
Procaine Topical  5mL Administered before 
Oral dosing  
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7.2.3. Habituation and housing 
A total of twenty large Yorkshire gilts were used for the in vivo analysis investigation. The 
pigs day and night cycles were controlled similar to their natural habitat, with 12 hour days 
and nights. The pigs were placed individually in separate cages, with a controlled 
environmental temperature of 25°C ± 3°C and fed at preset times. The habituation was a 
period of 4 weeks, with regular twice a day visits to the pigs by the researchers. This period 
allowed the pigs to acclimatize to their new environment and to reduce any kind of social 
stress to the pigs. 
 
7.3. Jugular venous catherisation for blood sampling 
The average weight the pigs weighed was between 30-35±2kg before catherisation. During the 
habituation process, after two weeks, the pigs were weighed and prepared for catherisation. 
Briefly, the catheter insertion into the jugular vein was as follows: The pigs were anesthetised with 
ketamine (I.M.), xylazine (I.M.), and topical procaine (to reduce prick pain) was applied. The pigs 
were maintained under an oxygen atmosphere during the insertion of the catheter into the jugular 
vein.The duration of the surgery for each pig was 3 hours. 
Briefly, an incision was made on the left side of the neck, directly above the jugular vein. The two 
lumen central venous catheter was then inserted into the lumen of the jugular vein. The length of 
the remaining catheter was then tunnelled subcutaneously dorsal to the scapula and out through 
the back of the neck (figure 7.2.). The catheter was used for the withdrawal of blood samples at 
predetermined time intervals without causing undue distress to the pig.  
Post-operative care included monitoring of the pigs for the duration of the study to ensure that the 
catheter (1) had been inserted properly, (2) no complications had occurred during the surgery and 
(3) during the insertion process. Heparine saline was be used to wash out the catheter twice daily, 
to prevent blood clots from forming which allowed for easy withdrawal of blood. 
Blood samples were withdrawn using one of the ports (white or brown). Firstly the ports were 
flushed with 5mL of heparinised saline to ensure there were no blood clots that had formed 
in each of the ports. Blood (5mL)was then withdrawn and the port was further flushed with 
another 5mL of heparinised saline after sample withdrawal.  
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Fig.7.2. Surgical incision of 2cm to access the jugular vein. The catheter was then inserted into 
the jugular vein on the right side of the neck. 
 
Fig.7.3. Catherter insertion surgery and post surgery. Once the catheters were inserted the pigs 
were then returned to their cages for full recovery. 
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7.3.1. Captopril gastric dosing and formulation testing 
The pigs weight had increased to 45-54±3kg on dosing. The pigs were allowed an overnight 12 
hour fasting period prior to testing. Baseline blood samples were withdrawn before the pigs were 
dosed, representing the zero time point.  
            
Fig.7.4. Oxygen was given and the pulse was monitored during the dosing of the pigs. 
 
Fig.7.5. Preparation for the oral administration of the drug delivery system. 
The pigs were anaesthetized (as described previously in Section 7.3) and oxygen was given 
to the pigs. The blood pressure was monitored continuously throughout the oral 
administration of the capsule procedure. Briefly, the pigs were held in an upright position 
while their mouths were kept open. Then an intragastric tube was inserted into the pigs’ 
mouths, until it reached the opening of the rumen. Once the tube was positioned the capsule 
was administered through the tube and water was used to flush the capsule down the tube 
to ensure that the capsule reached the rumen. The intragastric tube was then pulled out and 
the pigs were returned to the cages. Blood withdrawals were taken over a period of 24 hour, 
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at 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 hours respectively, with catheter maintenance procedures 
being followed between each withdrawal. 5mL of the blood was collected into EDTA 
vacutainers (BD Vacutainers, Franklin Lakes, NJ, USA) to prevent blood coagulation (Figure 
7.3.). An overall flow diagram of the in vivo animal study experimentation procedure was 
illustrated in Scheme 7.2.  
 
 
 Scheme 7.2. Summary of the in vivo animal studies experimentation procedure. 
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7.4. Ultra Performance Liquid Chromatography for blood analysis 
Quantitative Analysis of the blood samples were tested using the Waters Acquity™ 
UPLC/MS/MS MS system (Waters Corporation, Milford, MA, USA).  
 
7.4.1. Chromatographic method for detecting captopril and hydrochlorothiazide in 
blood plasma  
The liquid chouromatography separations were achieved using the Acquity UPLC® BEH shield 
RP18 1.7µm, 2.1 x 150mm column. The mobile phase contained acetronitrile and the 
aqueous component (0.1% formic acid) in volumetric proportions 10:90. The separation was 
achieved isocratically in a maximum time of 2.5 minutes. The step gradient method to 90% 
ACN in 0.01 minutes, followed by another isocratic plateau of 1.2 minutes, was used for a 
run to run washout (for elimination of residual endogenous matrix having an increased 
apolar character).  The initial mobile phase composition was obtained after another stepwise 
modification of the mobile phase composition in 0.01 minutes and column equilibration took 
0.5 minutes. The complete separation cycle took 3.5 minutes. The temperature of the 
column was set at 40°C with a flow rate of 0.25mL/min and an injection volume of 5µL was 
used. The internal standard chosen for the study was hydrochlorothiazide, a potent 
antihypertensive drug.     
 
7.4.2. Preparation of the hydrochlorothiazide and captopril calibration curves in 
plasma 
Individual stock solutions of 0.1mg/mL of the hydrochlorothiazide and captopril were 
prepared separately. Stock solutions (50µL) were then used to spike 500µL of blank blood 
plasma for calibration.    
 
7.4.3. Extraction of bioactives in blood plasma  
There are two phases to the sample preparation procedure: 
1) Derivation which includes the separation of the blood plasma and the red blood cells 
2) The protein precipitation in which all the protein in the plasma is precipitated out.  
In the first phase 40mL of whole blood were collected into the anticoagulant and were 
centrifuged. On completion the plasma was separated using a micropipette. 1mL of the 
aliquot was mixed with the internal standard solution (0.1mL, 500ng/mL in aqueous 0.1% 
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formic acid), followed by the addition of the derivatisation reagent solution (0.05mL, 4mg/mL 
in acetonitrile). After vortexing (15 seconds at 2500 rpm), the solution was rested for 30 min 
for the completion of the derivatization. The samples were then frozen at -70°C and stored 
until further analysis was required.  
The second phase consisted of the unassisted thawing of the samples in phase 1, at room 
temperature. After thawing the 0.2 mL of plasma was aliquoted in 0.4 mL of acetronitrile for 
protein precipitation. The mixture was then vortexed for 5 min at 2500 rpm and centrifuged at 
3000 rpm for 10 min. The supernatant was injected into 2.5 mL vials after a further dilution 
with 0.4 mL of deionised water. Five microliters were then injected onto the 
chouromatographic column.   
The derivatization was performed immediately after the blood samples were withdrawn and 
the plasma preparation procedure was performed. This was done to increase the stability of 
the drug over the storage period under the freezing conditions. It should be noted that 
without the derivatization process, captopril would quantitatively oxidise to disulphide bonds 
over a period of three months at a storage temperature of -70°C. The internal standard was 
added prior to the addition of reagents, as well as the target compound due to its thiol 
functional group. It was expected that the internal standard would behave similarly to 
captopril, throughout the analytical method. To eliminate the focussing effects, water was 
added as a dilution solvent, especially when using a 90% acetonitrile aqueous phase during 
the chouromatographic run. 
 
7.5. Pharmacokinetic modelling and analysis of captpril and hydrochlorothiazide in 
vivo 
The pharmacodynamics and pharmacokinetics were analysed using the PKSolver excel 
spreadsheet addition. The obtained data was used to model the trends in the 
pharmacodynamic and pharmacokinetic parameters. The evaluation of bioequivalence was 
made by the pharmacokinetic parameters AUCtotal (area under plasma concentration-time 
plot until the last quanitifiable value) and Cmax observed (maximum plasma concentration) for 
captopril. Secondary (Tmax sampling time of the maximum plasma concentration) and 
auxillary (Thalf terminal elimination half-life; percentage of AUCextra with respect to AUCtotal; 
MRT, mean residence time) parameters were also determined. 
 
 
119 
 
7.6. Results and Discussion 
7.6.1. Method validation for captopril and hydrochlorothiazide in blood plasma 
The detector response function was evaluated over the the concentration interval 2.5ng-
1mg/mL, for blood plasma spiked with free captopril and prepared at six concentrations as 
described above in section 7.4.2. Three replicates were prepared for each concentration 
level. Relative standards deviations calculated at each of the concentration levels ranged 
from 0.1- 1.0%. The response function was found to be non-linear over the studied interval, 
also found (Georgita et al.,2008 and Medvedovici et al.,2009). To achieve linearization, the 
logarithim (10 base) of the peak ration of captopril and internal standard derivation was 
represented against the logarithim of concetration. The log-log function was linear, being 
characterized by a correlation coefficient of 0.997, as seen in Figure 7.6, i and ii. The relative 
standard deviations found in each concentration of spiked plasma ranged between 3.2-7.6% 
interval for both captopril and hydrochlorothiazide. 
 
7.6.2. Recovery efficiency of captopril and hydrochlorothiazide 
Recovery of free captopril was evaluated by comparing the spike of captopril made in 
deionised water and blank plasma at 100ng/mL. Three replicates were made for the 
specified concentration level. Recovery was calculated as the percentage peak area in the 
chromatograph of the spiked captopril plasma from the peak area in the chromatogram of 
the corresponding spiked water sample. The internal standard was also considered for 
evalution of the recovery at a single concentration level of 100ng/mL. The mean percentage 
recovery of captopril was 88% with a normal variation of ± 4, ranging between 84 and 92%. 
For the internal standard mean recovery was calculated as 92%, with variation between 89 
and 95%. These results demonstrate that the plasma matrix did not affect the derivation, 
isolation of the derivatives, their separation or ionization. 
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Fig.7.6. (i) Construction of the captopril calibration curve, (ii) hydrochlorothiazide abstracted 
from pig blood plasma. 
 
121 
 
7.6.3. In vivo blood analysis of captopril and hydrochlorothiazide  
7.6.3.1. Captopril and hydrocholorothiazide analysis using Ultra Performance Liquid 
Chromatography (UPLC) 
The blank plasma samples did not yield any peak at the retention times of the analytes, 
when compared to the spiked drug samples, which indicated there was no interference and 
selectivity of the developed chouromatograph method.  
Figure 7.7 demonstrates the successful separation of captopril and hydrochlorothiazide from 
the spiked pig blood plasma. The UPLC assay method continued to perform in terms of 
accuracy in each analytical run. The method was successfully applied to accurately measure 
free captopril concentration on a large number of pig plasma from the bioequivalence study. 
A peak plasma concentration was observed generally about one hour after drug 
administration (Ohman et al., 1985). It was readily converted to its disulphide dimers and 
forms disulfide conjugates with endogenous thiol compounds. The major metabolic pathway 
for captopril involves not only the formation of its disulfide dimer but also of mixed 
conjugates with endogenous thiol-containing compounds and plasma proteins Srinivas et al., 
2003). The disulfide metabolites of captopril are inactive and there was evidence for their 
conversion back to the active form in vivo (Hadjmohammadi et al., 2008). This observation 
could explain the lack of concentration effect relationship for captopril metabolites. Figure 7.8 
represents the concentration of blood plasma captopril from the ovalbumin captopril carrier 
system. It was evident that the concentrations of captopril in vivo were maintained constant, 
demonstrating the sustained release of captopril over the 24 hour period. 
 
 
Fig.7.7. Separation of captopril and internal standard derivatives with hydrochlorothiazide 
from spiked plasma samples. Captopril was measured at a retention time of 1 minute and 
2.2 minutes for hydrochlorothiazide. 
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Fig.7.8. in vivo plasma concentration of captopril collected for 24 hours. The collection points 
represent times 2=4hr, 4=8hr, 6=12hr, 8=16hr, 10=24hr. 
  
7.6.3.1.2. Comparison of the pharmacokinetics parameters of the ovalbumin captopril 
carrier system against the conventional 
The maximum reached concentration time curve (Cmax), area under the plasma 
concentration–time curve from 0 hour to the last measurable (AUC0 – 24 hour) and area 
under the plasma concentration–time curve from 0h to infinity (AUC0 – ∞) were compared 
and pharmacokinetic parameters were computed using WinNonlin Professional Software 
Version 4.0.1. Statistical calculations were defined at the level of P≤0.05. Bioequivalence for 
Capoten® and the ovalbumin drug carrier system formulations was concluded as the 95.0% 
confidence interval for Cmax, AUC0 – t and AUC0 – ∞ fell within the range of 80.0–95.0% 
defined by both the Food and Drug Administration (FDA). According to literature the half-
time of captopril was reported as 1-2 hour (Ohman et al., 1985), but in the ovalbumin drug 
carrier delivery system it was 5.6 hours. Pharmacokinetic parameters calculated for free 
captopril are represented in Table 7.2. From the experimental data, the bioequivalence 
between the two tested pharmaceutical formulations was determined with respect to the rate 
and extent of captopril absorption. The concentrations of captopril in vivo were within the 
therapeutic range. 
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Table 7.2. Statistic interpretation of pharmacokinetic parameters corresponding to captopril 
in tested pharmaceutical formulations against the reference (conventional) product. 
Pharmacokinetic 
parameters 
 O 
Mean      SD 
    Conventional 
Mean          SD 
Geometric mean 
ratio 
AUCtot (ng/mL h) 625       37.2 526           26.7 1.188 
AUClast (ng/mL h) 625       25.9 526           24.5 1.188 
Cmax (ng/mL) 33.8      5.9 33.2          6.2 1.018 
Tmax (h) 12         2.0 16             3.6 1.333 
%AUCextra 0            - 0                - 0 
Thalf (h) 5.65       3.9  1.42        0.29 1.275 
MRT 7.83      34.7 2.44        8.7 3.558 
Emax (%) 0.046      - 0.022          -     - 
EC50 (ng/mL) 4.074      - 0.499          -     - 
R 0.929      - 0.753          -     - 
Tmax, time to maximum concentration; Cmax, maximum concentration; AUC0–t, area under 
the curve of plasma concentration until the last concentration observed; AUC0–∞, area 
under the curve between the first sample and infinitive; T1/2, elimination half life.     
                             
7.7. Concluding Remarks                                                                                           
The ovalbumin drug carrier system demonstrated improved, drug release profiles in vivo, in 
addition increased the mean residence time, the half life and produced maintained relativeltly 
constant captopril concentration. There was correlation between the in vivo and in vitro drug 
release proflies of the ovalbumin drug carrier system, which proves that the system provided 
a better drug delivery system. The pharmacokinetic parameters determined in vivo also 
provide substantial evidence of a better drug delivery sytem in comparison to the 
conventional. 
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CHAPTER 8 
Conclusions and Recommendations 
8.1. Conclusions 
The synthesis of a multifunctional drug carrier system was to enable the bioconjugation of 
any thiol containing bioactive while remaining stable in vitro and in vivo. The novel ovalbumin 
polymer was used as the carrier because of its natural internally buried disulphide bonds that 
would provide an excellent potential site for bioconjugation. The FTIR was used to firstly 
monitor the reduction of the disulphide bonds buried in the interior of the ovalbumin polymer, 
resulting in the exposure of the resultant functional thiols. This process provided insight into 
the chemical behaviour of these functional thiols groups, in terms of their chemical 
properties. The thiols were successfully conjugated with the anti-hypertensive, captopril, 
resulting secondary conjugation of the ovalbumin thiols to an external source of thiols, 
forming disulphide bonds. The thiol redox responsive mechanism makes this system a novel 
innovative system for creating thiol functionalised drug delivery systems.  
Inorder to create a drug delivery system, sodium alginate was used. Sodium alginate 
contains thiols that helped enable additional conjugation to ovalbumin and captopril thus 
allowing for the formation of a prolonged controlled drug delivery system. The successful 
Ovalbumin Drug Carrier Drug Delivery System was formulated.  
Characterisation techniques were used to assess the, which include rheology, FTIR and the 
differential scanning calorimetry. These characteristics were determinable and employable 
for the characterisation of the drug delivery system. The extensive in vitro preliminary testing 
of each formulation was accomplished to produce an optimized design. Preliminary 
evaluation of dissolution and drug entrapment testing of the ovalbumin captopril carrier 
system established upper and lower limits for variant formulation parameters of ovalbumin 
polymer concentration, calcium chloride crosslinker and sodium alginate concentration. 
Similarly, the variables were deduced through dissolution. 
A total of 15 formulations of the ovalbumin captopril carrier system were analysed by the 
Box-Behnken factorial design after individual formulation. The responses that were tested 
were fractional drug release, DEE and MDT. The average particle sizes and zeta-potentials 
were determined. 
 
The optimised formulation produced improved drug release percentage, retention time and a 
prolonged controlled drug release system. The fabrications of the ovalbumin captopril carrier 
system particles were found to be spherically layered, with high drug entrapment. 
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Furthermore the mechanical strength and thermal of properties of the particles were found to 
be improved with the conjugation of the hydrogel and the crosslinker.  
 
There was correlation between the in vivo and in vitro drug release of the ovalbumin 
captopril carrier system, which proves that the ovalbumin captopril carrier system provides a 
better drug delivery system because of the higher levels of captopril at 24 hour. The 
pharmacokinetic parameters determined in vivo also provide substantial evidence of a better 
drug delivery sytem in comparison to the conventional. 
 
This study provides valuable information that can be employed in developing novel drug 
carriers for application in the oral delivery of thiol reactive drugs. The Box-Behnken quadratic 
design employed for the synthesis of the ovalbumin carrier system revealed the impact of 
thiol reactions on the physicochemical properties due to the variations in the levels of 
independent variables employed during the process of fabrication. The conjugation of the 
thiols to form disulphides, and the addition of a hydrogel proved to be efficient methods for 
the construction of the system. This indicates the efficiency of these methods as particles 
retained the contributing effects of individual chemical compounds characteristics that 
comprised each formulation. The physicochemical characteristics observed with the 
formulation imply that the carrier system explored in this investigation can be described as 
versatile which can make them attractive for the adaptive invention and construction of novel 
drug delivery systems. The statistical analysis data also confirmed the dependency of the 
measured physicochemical response parameters on the independent level. Physicochemical 
parameters which were selected, related to the application of the system, included particle 
size, zeta-potential, drug release and the mean dissolution time. The response and fitted 
values were closely related, indicating adequacy and reliability of the statistical design 
employed. Conclusively an optimised formulation was successfully design and the 
physicochemical properties revealed the potential of this matrix to be applied prolonged drug 
release systems. 
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8.2. Recommendations 
The recommendations that could be made on the system would be to improve the 
bioconjugation of captopril to ovalbumin, using a more rigorous method such as photo-
polymerization. This would better ensure disulphide bond formation between polymers.  
The in vivo analysis in the pig model posed a good choice for the analysis of the drug 
release, but the system would have to be tested in a human model to better improve and 
understand the mechanism of release. The ODCDS was found to be limited to thiol based 
bioactives, such as peptides and proteins. Maybe a broader ability of thiols to bind to a range 
of other chemical functional groups, such as halogens, epoxy and isocyanates would make 
this system a more approachable and user friendly site specific bioconjugation system. 
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APPENDIX:  B.1. 
 
Potential Publications: 
 
Disulphide/Thiol Chemistry: A Multifaceted Versatile Tool for Macromolecular Design 
and Synthesis of Polyfunctional Material and Polymer for Drug DeliveryAbstract 
The review highlights recent interests and applications of disulphide and thiol chemistry in 
creating contemporary macromolecular designs. Due to the chemical nature of disulphides 
and thiols a wide range of chemical species react with these functional groups to yield a 
variety of polymers extending their applications in chemical, biological, physical, material 
engineering and material sciences. The review aims to illustrate the versatility and 
demonstrate the potential of thiol-based chemistries. The focus is on exploring bio-cleavable 
disulphides and linking by “clicking” thiols via thiol/other functional group exchange 
reactions. Thiol synthesis, modification and functionalization are demonstrated to be highly 
attractive and efficient in polymer and material science. The review also illustrates the 
remarkable pliability of synthetic and natural approaches to designing, optimizing and 
functionalizing nanostructures and conjugates by thiol chermistry modification. The 
examples quoted in the review illustrate the power and versatility of thiols for site specific 
functionalization, the construction of complex macromolecules and the generation of both 
biodegradable disulphides and non-biodegradable bonds. In addition, the ability of thiols to 
react with various functional groups found in a variety of polymer science materials and 
biological entities such as peptide and related structures will also be demonstrated. In spite 
of the fact that research efforts in thiol chemistry are still at the early stages, it is likely that its 
true potential will be developed.  
Keywords: Bio-cleavable disulphides, disulphide chemistry, macromolecules, 
nanostructures, thiol chemistry 
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Optimisation of the Novel Polyfunctionalised Drug Carrier System. 
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ABSTRACT 
As part of the developing novel drug delivery systems, thiol-based chemical reactions are 
distinctive role players in stabilizing macromolecules for use in material science especially in 
polymer interactions. This research focused on the construction, characterisation and 
optimisation of the thiol conjugated complex for sustained oral drug delivery. An interphase, 
co-particulate homogenization technique and lyophilisation guided through a Box Behnken 
experimental design was employed in the synthesis, characterisation and optimization of the 
15 thiol carrier drug delivery systems. The results demonstrate the successful conjugation of 
the protein to the drug as demonstrated by the FTIR and differential scanning calorimetry 
results. The effects of different factor levels on the characterisation in vitro physicochemical 
performances of the thiol carrier drug delivery systems were explored. Drug loading was 
achieved (38-46±7.2mg). Overall amount of drug release in 24 hour was measured by the 
mean dissolution time value which ranged between 3.015-7.12 hours and demonstrated 
zero-order drug release profiles. The formulation demonstrated significant levels of the zeta 
potential which ranged between -13.6 ± 0.53 and -29.4±0.31mV. The size of the particles 
were measured (99.78±7.23 and 255.6± 23.73). The particles were mostly spherical in 
shape. Statistical constraints were simultaneously set to obtain levels of independent 
variables that optimised the thiol carrier drug delivery system. The investigation 
demonstrates the potential use of natural proteins in designing, optimising and 
functionalising nanostructures and conjugates by thiol chemistry modification. In conclusion, 
our validated method was successfully applied to pharmacokinetic studies of thiol containing 
bioactives in plasma samples. 
 
KEYWORDS: Thiol, disulphide bonds, ovalbumin, captopril, conjugate. 
